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ABSTRACT 
 
Alterations of NMDA and GABAB Receptor Function in Development: A Potential 
Animal Model of Schizophrenia 
 
by 
 
Monica Bolton 
 
Dr. Jefferson Kinney, Examination Committee Chair  
Assistant Professor of Psychology 
University of Nevada, Las Vegas 
 
Schizophrenia is a debilitating mental disorder that affects up to 3% of the world 
population. The behavioral symptoms are categorized into positive and negative 
symptoms, which appear during late adolescence/early adulthood. Unfortunately, the 
underlying cellular and molecular mechanisms of the disease are poorly understood. 
Several hypotheses exist to explain mechanisms contributing to these behavioral 
alterations. One model proposes that a reduced function of the NMDA glutamate receptor 
on specific GABAergic interneurons may be responsible for deficits in schizophrenia. 
Post-mortem investigations provide evidence of reductions in both glutamate and GABA-
related proteins in patients with schizophrenia. Further, GABAergic interneurons that are 
activated by glutamate via NMDA receptors are important for oscillatory activity 
involved with sensory processing and cognitive function. Alterations in the function of 
NMDA receptors on GABAeric interneurons are implicated in regulating neural network 
activity and, if disrupted, could potentially lead to altered brain function and deficits seen 
in schizophrenia. Several investigations have demonstrated reduction in NMDA receptor 
function or GABA receptor function induces deficits consistent with schizophrenia.  
Recent approaches have also focused on changes in NMDA or GABA function related to 
iv 
 
schizophrenia as a neurodevelopmental disorder. This approach suggests that alterations 
in either system during brain development may result in behavioral deficits later in life. 
The purpose of the below studies was to determine if changes in NMDA receptor 
function or alterations in downstream GABA receptor function during development in 
rodent pups results in behavioral or biochemical alterations in adulthood that are relevant 
to schizophrenia. The data reveal that altering these receptor systems in development 
produce deficits in adulthood. Changes in sensorimotor gating, spatial learning and 
memory, and differential expression of multiple GABA related proteins in the brain 
tissue were observed in these animals.   
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CHAPTER 1 
INTRODUCTION 
 While the etiology of schizophrenia is not known, several behavioral symptoms 
exist that characterize the disorder. Patients suffer from a combination of symptoms 
including hallucinations and delusions (positive symptoms), as well as deficits in 
sensorimotor gating, learning, and memory (negative symptoms) and others. Although 
the symptoms appear during early adulthood or late adolescence, the disorder may 
originate from an unknown neurodevelopmental abnormality (Weinberger, 1987). 
Numerous studies have been carried out in order to better understand the cellular and 
molecular basis of this disease in order to effectively treat patients.  
 One of the current hypotheses to explain the pathophysiology of schizophrenia 
proposes that there is a reduction in glutamate and γ-aminobutyric acid (GABA) 
signaling in the brain. Specifically, a reduction of the N-methyl-D-aspartate (NMDA)-
type glutamate receptor function on GABAergic interneurons produces altered network 
function and deficits associated with schizophrenia (Javitt, 2007). Administering drugs 
which block the NMDA receptor in healthy individuals produces behavior that is similar 
to the positive and negative symptoms observed in schizophrenic patients, and these 
drugs exacerbate symptoms in schizophrenic patients (Adler et al., 1999; Javitt & Zukin, 
1991; Krystal et al., 1994; Lahti et al., 1995; Luby et al., 1962). Post-mortem 
investigations of schizophrenia populations also reveal a reduction in specific subunits of 
the NMDA receptors and several protein markers associated with GABAergic 
interneurons (Benes & Berretta, 2001; Bullock et al., 2008; Hashimoto et al., 2003; 
Mirnics et al., 2000; Torrey et al., 2005). These proteins include glutamate decarboxylase 
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67 (GAD67; enzyme required for GABA synthesis; Akbarian et al., 1996; Kaufman, 
Houser, & Tobin, 1991; Volk et al., 2000) and parvalbumin (PV; a calcium binding 
protein; Beasley & Reynolds, 1997). Many behaviors depend on the activation of 
GABAergic interneurons via glutamate binding to NMDA receptors including network 
oscillations involved in learning and memory and cognitive function, as well as the 
development of neural networks during brain development. 
 GABA signaling is imperative for initiating and maintaining neural network 
oscillations (Gonzalez-Burgos & Lewis, 2008). Data suggests that the negative symptoms 
and cognitive deficits seen in schizophrenic patients may arise from abnormal oscillatory 
activity (Gonzalez-Burgos, 2010; Lewis, Hashimoto, & Volk, 2005; Uhlhaas & Singer, 
2010). NMDA receptor hypofunction on GABAergic cells could result in a reduced 
amount of GABA release. GABA release from these neurons inhibits a large population 
of downstream postsynaptic excitatory neurons, allowing them to become entrained into a 
synchronous firing pattern once the inhibition subsides (Roopun et al., 2008). GABA 
binds to both ionotropic (mainly GABAA) and metabotropic (GABAB) receptors. Binding 
to GABAA receptors results in fast-acting and short-lived inhibition (Macdonald & Olsen, 
1994; Watanabe et al., 2002) whereas activation of GABAB receptors results in a slower 
onset but long-lasting inhibitory effect (Kerr & Ong, 1992). The GABAB receptors have 
been shown to be important in maintaining oscillatory activity due to their sustained 
inhibitory properties (Scanziani, 2000). A reduction of GABA release or binding to 
receptors could result in asynchronous firing and possibly the abnormal oscillatory 
activity seen in schizophrenia patients.    
3 
 
Animal models of schizophrenia provide valuable insight into the mechanisms 
that may be involved in the disorder. Administration of ketamine (an NMDA receptor 
antagonist) to adult rodents produces deficits in sensorimotor gating, spatial learning and 
memory, and fear associative learning similar to what is seen in the patient population 
(Bolton et al., 2012; Cilia et al., 1997; de Bruin et al., 1999; Mansbach and Geyer, 1991; 
Sabbagh et al., 2012). Drugs that alter GABAB receptor function are less well studied in 
learning and memory and have been largely excluded for any potential role in 
schizophrenia. A limitation in the above studies is that they rely on drug being active at 
the time of testing. An alternative approach that may also allow investigators to 
incorporate the developmental theory of schizophrenia would be to administer drugs that 
target this system during development and test for behavior in adulthood.   
 A wealth of data examining brain morphology, protein expression changes, 
genetics, environmental factors, and gene-environment interactions suggests that some of 
the pathology leading to schizophrenia occurs during early brain development (Fatemi & 
Folsom, 2009; Lewis & Levitt, 2002; Lewis et al., 2004; Rapoport et al., 2005; 
Weinberger, 1987; Weinberger & Lipska, 1995). NMDA receptors and GABA signaling 
contribute to major developmental processes including neuronal migration, 
synaptogenesis, and incorporation of neurons into neural networks (Komuro & Rakic, 
1993; LoTurco, Blanton, & Kriegstein, 1991; Uhlhaas et al., 2010). An alteration in these 
receptor systems at critical brain developmental periods may have particular relevance to 
behavioral disturbances.  
 The purpose of this study was to determine if disrupting the function of NMDA or 
GABAB receptors in early life produces deficits consistent with schizophrenia in 
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adulthood. Our data demonstrate that a brief pharmacological alteration in NMDA 
receptor function and, separately, GABAB receptor function during early brain 
development of rat pups, results in altered behavior in adulthood in tasks that measure 
sensorimotor gating (using prepulse inhibition) and spatial learning in the Morris water 
maze. The most striking differences in these studies were differences between males and 
females receiving the same treatments, specifically the GABAB receptor antagonist 
(phaclofen) producing the most robust deficits. We also identified numerous changes in 
the tissue analysis in GABA related proteins as well as a marker for synaptic formation. 
These results suggest that alterations in of NMDA and GABAB receptors in brain 
development can produce lifelong impairments that may be related to neuropsychiatric 
disorders.  
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CHAPTER 2 
REVIEW OF RELATED LITERATURE 
Schizophrenia 
Schizophrenia is a debilitating brain disorder which affects up to 1-3% of the 
population with symptoms that cause lifelong impairments and disability (Rossler et al., 
2005). The clinical diagnosis is usually made in late adolescence or early adulthood when 
the symptoms typically first occur. These symptoms manifest into a constellation of 
behavioral abnormalities that are classified into either positive or negative subgroups. 
Characteristics of the positive symptoms include auditory hallucinations, delusions, and 
paranoia (Kay et al., 1987). Negative symptoms can be described as a deficit compared to 
the normal population. They leave patients with impairments in sensorimotor gating, 
attention, abstract reasoning, mental flexibility, learning and memory, affect, and certain 
aspects of information processing (Carter et al., 1996; Rushe et al., 1999; Swerdlow et al., 
1994). Because of these deficits, patients are left with a lifetime disability in a variety of 
everyday functional and social domains (Burns, 2007; Green, Kern, Braff, & Mintz, 
2000). Unfortunately, the etiology of schizophrenia is not known but there have been 
various cellular/molecular mechanisms proposed to account for the disorder. 
Several neurochemical hypotheses have been suggested to explain the 
pathophysiology of schizophrenia. The discovery of dopamine antagonists’ utility as an 
antipsychotic in the late 1950s suggested that dopamine has a role in the disorder. 
Dopamine is a monoamine neurotransmitter and has been shown to mediate multiple 
systems within the central nervous system (CNS); most importantly, it plays a major role 
in reward systems (Schultz, Dayan, & Montague, 1997) and motor function 
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(Korchounov, Meyer, & Krasnianski, 2010). The specific role of dopamine in 
schizophrenia remains to be identified; however, data indicate that antipsychotics 
alleviate positive symptoms by modifying dopamine receptor function, which suggests a 
dysregulation of dopamine in schizophrenia. Investigations of dopamine alterations in 
schizophrenia populations include the evaluation of post-mortem tissue, imaging in 
patient populations, and numerous animal models of dopamine dysfunction relevant to 
the disorder (Bird et al., 1977; Crow et al., 1979; Davis, Kahn, Grant, & Davidson, 1991; 
Elkashef et al., 2000; Haberland & Hetey, 1987; Howes & Kapur, 2009; Toru, 
Nishikawa, Mataga, & Takashima, 1982). Data from these studies have provided mixed 
evidence for altered dopamine in discrete brain regions as being associated with 
schizophrenia. These data also have provided the foundation for what is termed the 
dopamine hypothesis (Carlsson, 1988; van Rossum, 1966), which argues that elevated 
dopamine activity in subcortical regions (the striatum and basal ganglia) is associated 
with the positive symptoms of schizophrenia, while reduced dopamine activity within the 
cortex may be associated with the negative symptoms (Davis et al., 1991; Pycock, 
Kerwin, & Carter, 1980). However, limitations to this theory exist. For instance, the 
means by which dopamine tone is elevated in some regions and reduced in others has not 
been elucidated. Additionally, antipsychotic medications only moderately alleviate the 
positive symptoms and have limited efficacy for the negative symptoms (Javitt & Zukin, 
1991). Although dopamine tone is altered in schizophrenia, the dopamine hypothesis 
does not account for the cause of these changes. 
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Glutamate Hypothesis of Schizophrenia 
A more recent alternative model hypothesized to explain the cellular/molecular 
alterations in schizophrenia is based on a combination of data from drug abuse literature 
and separate post-mortem examinations of schizophrenia populations. The model 
proposes that there is a reduction in glutamate signaling within discrete circuits of the 
brain, which may account for the behavioral symptoms of schizophrenia and also may 
cause alterations in dopamine signaling. Glutamate is the main excitatory 
neurotransmitter in the brain. Activation of glutamatergic receptors results in excitation 
of both excitatory and inhibitory neurons through a variety of receptors, including the 
NMDA receptor. The initial investigation of the NMDA receptor as it relates to 
schizophrenia began with individuals who abused drugs that block these receptors 
(ketamine and phencyclidine; NMDA receptor antagonists). The effects of the abuse of 
these drugs as well as observations from previous studies with controlled administration 
of NMDA receptor antagonists to healthy volunteers showed that NMDA receptor 
antagonists are capable of mimicking the cognitive and behavioral symptoms of 
schizophrenia in healthy individuals (Adler et al., 1999; Krystal et al., 1994; Luby et al., 
1962). Additionally, abuse of ketamine or phencyclidine (PCP) by schizophrenic patients 
has been demonstrated to exacerbate schizophrenia symptoms and produce psychosis in 
stable patients (Javitt, 1987; Lahti et al., 1995; Luby et al., 1962). These early 
observations provide support that the NMDA receptor may be involved in the disorder.   
NMDA receptors play an important role in learning and memory, cognition, and 
sensory processing. In the hippocampus, NMDA receptors are necessary for long-term 
potentiation (LTP), a process in which the synaptic connections between two or more 
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neurons that fire together are strengthened (Bliss & Lomo, 1973; Bliss & Collingridge, 
1993; Hebb, 1949). This process is hypothesized to be vitally important for learning and 
memory and is strongly linked to new memory formation. Pharmacologically blocking 
the function of NMDA receptors leads to impaired cognition, learning, immediate recall, 
and long-term retention (Lee et al., 1993; Ohno, Yamamoto, & Watanabe, 1994).  
NMDA receptors are unique because they are both ligand and voltage-gated 
receptors. While the binding of glutamate and glycine to the NMDA receptor will induce 
a conformational change in the receptor, the presence of a magnesium (Mg+) ion bound 
to the inside of the channel at resting membrane potential (-65 mV) prevents the passage 
of any ions through the channel. When the membrane is depolarized by non-NMDA 
glutamate receptors (AMPA and kainite), the Mg2+ ion is driven out of the channel by 
electrostatic repulsion, allowing the channel to open and calcium (Ca2+) to enter (Mayer, 
Westbrook, & Guthrie, 1984; Nowak et al., 1984).  The influx of Ca2+ into the cell leads 
to an increase in membrane potential, as well as the activation of a variety of Ca2+ 
dependent second messenger systems (Kleinschmidt, Bear, & Singer, 1987). Therefore, 
activation of the NMDA receptor requires a unique combination of ligand binding and 
membrane depolarization.  
NMDA receptors are composed of subunits termed NR1, NR2, and NR3. All 
functional NMDA receptors contain one NR1 subunit and either one of several possible 
subunits of NR2 (NR2A-D) or NR3 (Monyer et al., 1992). Different subunit assemblies 
of NMDA receptors contribute different functional properties of the receptor, including 
the strength of the Mg2+ block, glycine sensitivity, and receptor occupancy (Ishii et al., 
1992; Kutsuwada et al., 1992; Monyer et al., 1992). For example, NR1-NR2A and NR1-
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NR2B channels are characterized by a stronger voltage sensitivity of the Mg2+ block (it 
takes a greater voltage change to dislodge the ion) compared to NR1-NR2C and NR1-
NR2D channels (Monyer et al., 1992). Because of the weaker Mg2+ block seen in the 
latter receptor channels, their function may be to detect relatively small postsynaptic 
depolarizations. Another functional difference between subtype assemblies is that NR2A-
containing receptor channels do not bind glutamate for very long (measured by offset 
decay time) compared to the other subtypes (Monyer et al., 1992). Consequently, NR1-
NR2B, NR1-NR2C, or NR1-NR2D receptors mediate longer-duration excitatory 
postsynaptic potentials as compared to NR1-NR2A receptors. Throughout a lifespan, the 
assembly of NMDA receptors differs (Akazawa et al., 1994). During development, NR1 
and all NR2 subunits are expressed at peak levels on postnatal day (PND) 7 in the rat 
brain (about third trimester for human brain development; Clancy et al., 2007); then, after 
PND 12, a distinct change in expression occurs for the NR2 subunits (Monyer et al., 
1994). There is a shift from the expression of NR2B and NR2D subunits, both of which 
are most abundant in the neonatal brain, to the expression of NR2A in the forebrain and 
NR2C in the cerebellum (Akazawa et al., 1994; Cull-Candy, Brickley, & Farrant, 2001; 
Monyer et al., 1994). Since many important cognitive processes depend on the NMDA 
receptors, altering their assembly and thus their activity can cause devastating effects.    
Alongside the previously mentioned drug abuse literature, complementary data 
from post-mortem examinations of schizophrenic patients have given further valuable 
insight into the possible glutamatergic changes that occur in the disorder. Not only is 
glutamatergic tone reduced in schizophrenia patients (Sherman et al., 1991; Squires et al., 
1993), differential expression of mRNA for the NR2A (increased levels) and NR2D 
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(decreased levels) subunits has been observed in the prefrontal cortex (Akbarian et al., 
1996). Additional changes include a reduction the NR1 subunit in the hippocampus 
versus healthy controls (Gao et al., 2010). These data suggest that not only is there an 
overall reduction in glutamate signaling, but there is also an alteration in the assembly 
and function of the NMDA receptor. 
GABA Signaling 
GABA is the main inhibitory neurotransmitter in the brain and is synthesized 
from glutamate by GAD67. GABAergic interneurons are responsible for inhibitory 
signaling that is vital for normal CNS function, including the regulation of network 
oscillatory activity. A necessary component of the activation of these GABAergic 
neurons comes from NMDA receptors. When glutamate binds, the receptors allow Ca2+ 
to enter causing the cell to depolarize and release GABA. These interneurons are very 
large compared to pyramidal neurons and connect onto many different excitatory 
postsynaptic neurons (e.g. dopamine, serotonin, glutamate). The rapid release of GABA 
onto the postsynaptic excitatory neurons produces a sustained inhibition. This inhibition 
entrains the postsynaptic neurons into a synchronous firing pattern and, once disinhibited 
(removal of inhibition), the neurons are then allowed to fire when receiving excitatory 
input from other cells. Based on the role of NMDA receptor function, it has been 
hypothesized that NMDA receptor-mediated excitation of GABAergic interneurons 
results in the inhibitory activity that drives network function. Numerous investigations 
have shown that NMDA receptors on inhibitory GABAergic interneurons are 
disproportionately more sensitive to NMDAR antagonists (Coyle, Tsai, & Goff, 2003; 
Grunze et al., 1996; Li, Clark, Lewis, & Wilson, 2002) and, more specifically, those that 
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contain PV may have relevance to schizophrenia (Beasley & Reynolds, 1997; Beasley e 
al., 2002; Coyle et al., 2003; Kinney et al., 2006; Morris, Cochran, & Pratt, 2005; 
Reynolds et al., 2001). These data suggest that a reduction in the function of NMDA 
receptors can cause a lack of inhibition in discrete brain regions that have PV+ 
GABAergic interneurons. The effect of this lack of inhibition is proposed to cause a 
disruption in the synchronous activity of downstream excitatory pyramidal neurons. 
GABAergic interneurons play an important role in the generation and entrainment 
of oscillations (Gonzalez-Burgos, 2010); therefore, neuronal synchronization is thought 
to rely on GABA-mediated inhibition. Gamma- and theta-wave oscillatory activity is 
suggested to underlie working memory and information processing between cortical areas 
and is related to cognitive function (Bartos, Vida, & Jonas, 2007; Cardin et al., 2009; 
Fries, 2009; Gonzalez-Burgos & Lewis, 2008; Roopun et al., 2008; Salinas & Sejnowski, 
2001; Sohal et al., 2009; Uhlhaas & Singer, 2010). Based on numerous studies, the 
cognitive deficits seen in schizophrenia may result from abnormal neuronal oscillatory 
activity (Gonzalez-Burgos, 2010; Lewis et al., 2005; Uhlhaas & Singer, 2010). 
Converging evidence suggests that the generation of oscillations, which are impaired 
during cognitive tasks in schizophrenic patients (Minzenberg et al., 2010; Spencer et al., 
2004; Woo, Spencer, & McCarley, 2010), depends on NMDA receptor-mediated 
transmission on PV+ GABAergic interneurons (Phillips et al., 2012; Sohal et al., 2009). 
Each PV+ GABAergic interneuron projects onto many excitatory neurons and 
disinhibition from one interneuron can desynchronize the majority of a local network, 
leading to a disruption in cortical processing (Moghaddam et al., 1997; Phillips et al., 
2012). Decreased expression of PV leads to increased asynchronous release of GABA 
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from PV+ GABAergic interneurons, which may result in a reduction in the ability of 
downstream excitatory neurons to integrate incoming stimuli, the functional consequence 
of which may be altered cognitive function and sensory processing (Javitt, 2009; Powell, 
Sejnowski, & Behrens, 2012; Uhlhaas & Singer, 2010). Although data provide evidence 
for a reduction in NMDA receptors and PV expression, the GABA receptors themselves 
may also play a role in desynchronization as it relates to schizophrenia.  
GABA binds to both ionotropic and metabotropic receptors in the central nervous 
system. Ionotropic GABA receptors (mainly GABAA) are ligand-gated ion channels 
permeable to chloride. Once GABA binds and activates these ionotropic channels, a fast 
acting inhibitory current is produced within the cell (Macdonald & Olsen, 1994). 
Conversely, the metabotropic GABA receptors (GABAB) are G-protein coupled receptors 
that are located both pre- and postsynpatically and produce a slow onset but longer 
lasting inhibition (Couve, Moss, & Pangalos, 2000; Kerr & Ong, 1992). Presynaptic 
GABAB receptors suppress neuronal Ca2+ conductance, leading to the inhibition of 
neurotransmitter release of the presynaptic neuron. Postsynaptic GABAB receptors 
increase membrane conductance to potassium (K+) leading to the hyperpolarization of 
postsynaptic neurons (Bettler e al., 2004; Bowery et al., 2002; Kohl & Paulsen, 2010; 
Misgeld, Bijak, & Jarolimek, 1995; Padgett & Slesinger, 2010). Functional GABAB 
receptors exist as heterodimers (Jones et al., 1998) comprised of a GABABR1 (contains 
binding site) and a GABABR2 subunit (contains regulatory G-proteins; Bowery et al., 
2002; Galvez et al., 2001; Kohl & Paulsen, 2010; Pinard, Seddik, & Bettler, 2010; 
Robbins et al., 2001). Compared to the function of the GABAB receptor, the function of 
the GABAA receptor is better understood because of its direct activation and fast 
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inhibition properties. Both GABAA and GABAB receptors are able to modulate GABA 
oscillations and LTP, which results in altered learning and memory functions (Scanziani, 
2000).   
Although the distinct roles the GABA receptors play in cognitive functions such 
as learning and memory are unclear, in vivo and in vitro studies have shown they are able 
to modulate neuronal oscillations. For instance, simultaneously blocking GABAA and 
GABAB receptor function in vitro facilitates theta frequency oscillations induced by a 
cholinergic agonist (Konopacki et al., 1997). Data from transgenic animals and 
pharmacological studies demonstrate that the GABAB receptor is vital for the stability of 
cortical circuits, possibly due to the longer lasting inhibitory properties of these receptors. 
GABABR1 knockout mice develop spontaneous seizures and premature death (Prosser et 
al., 2001; Schuler et al., 2001); meanwhile, high doses of GABAB receptor antagonists 
administered to adult rodents induce hippocampal and neocortical seizures (Leung, 
Canning, & Shen, 2005; Vergnes et al., 1997). However, the data regarding cognitive 
task performance and learning and memory are limited and inconsistent. Several studies 
indicate that low dose GABAB receptor antagonists enhance (Getova & Bowery, 2001; 
Helm et al., 2005; Leung & Shen, 2007; Mondadori, Jaekel, & Preiswerk, 1993; 
Mondadori, Mobius, & Borkowski, 1996; Staubli, Scafidi, & Chun, 1999) or do not alter 
cognitive task performance compared to controls (Zarrindast et al., 2002). Studies using 
GABAB receptor agonists are similarly inconsistent and sometimes contradictory 
(Myhrer, 2003). The incongruent results from GABAB receptor ligands may be due to the 
fact that the receptors are located both pre, post, and extrasynaptically and any functional 
effect of the ligand may not produce straightforward results.  
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Similar to what is found in post-mortem investigations with NMDA receptor 
subunits, GABAB receptors are also decreased in the prefrontal cortex and hippocampus 
of schizophrenic patients (Ishikawa et al., 2005; Mizukami et al., 2000; Mizukami et al., 
2002). Post-mortem analysis in schizophrenia populations have shown consistent 
alterations in GAD67 and PV expression in the hippocampus and prefrontal cortex 
(Beasley & Reynolds, 1997; Benes et al., 1991; Bullock et al., 2008; Hashimoto et al., 
2003; Mirnics et al., 2000; Reynolds, Zhang, & Beasley, 2001; Torrey et al., 2005). Since 
both of these proteins are specific to GABAergic interneurons, these data suggest that 
GABA signaling may be altered in the disorder as well.  
As previously discussed, the hypofunction of NMDA receptors may result in the 
disinhibition of GABAergic interneurons. It is also possible that the receptors to which 
GABA binds may be differentially expressed, such that a similar disinhibition occurs. If 
there is a reduction in pre- or postsynaptic GABAB receptor function, an alteration in the 
release or binding of GABA potentially results in asynchronous activity. Disrupting the 
function of either NMDA receptors or GABAB receptors could conceivably result in the 
same change in oscillatory activity that has been speculated to occur in schizophrenia.  
Animal Systems to Model Mechanisms of Schizophrenia 
Although schizophrenia is an inherently human disorder, certain symptoms can be 
tested in rodent models. For instance, prepulse inhibition to test for sensorimotor gating is 
often examined in animal models of schizophrenia, as well as to test the potential efficacy 
of novel antipsychotics (Swerdlow, Braff, & Geyer, 2000). Additionally, the Morris 
water maze is utilized to look for spatial learning and memory deficits and cued and 
contextual fear conditioning is used to investigate associative fear learning. As noted 
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above, schizophrenia patients exhibit deficits in all of these tasks, suggesting the 
impairments may have relevance to the disorder.  
Sensorimotor gating can be described as the ability to filter extraneous noise from 
meaningful sensory inputs (Freedman et al., 1987). Patients have been characterized as 
being hypervigilant and sensitive to distracting sounds whereby their inability to gate 
stimuli makes them feel “flooded” by sensory stimulation (Venables, 1964). 
Sensorimotor gating can be measured in a task called prepulse inhibition (PPI) in both 
human and animals. PPI refers to the normal reduction of a startle response when a 
startling stimulus is preceded by a weaker, non-startling stimulus (prepulse). The theory 
is that the prepulse evokes an inhibitory response of the motor reflex that reduces the 
response to the startle stimulus (Braff & Geyer, 1990; Swerdlow, Geyer, & Braff, 2001). 
PPI is observed in neuropsychiatric disorders and can be modulated by drugs of abuse 
(Braff & Geyer, 1990; Geyer & Braff, 1987). Since PPI occurs on the first exposure of a 
prepulse-startle trial, it does not reflect a learned behavior but a reflexive response 
(Fendt, Li, & Yeomans, 2001; Graham, 1975; Hoffman & Wible, 1970; Ison, McAdam, 
& Hammond, 1973; Koch, 1999). Patients with schizophrenia startle similarly regardless 
of whether the startle stimulus is preceded by a non-startling, weaker prepulse, suggesting 
the prepulse does not inhibit this reflexive response as seen in healthy controls (Geyer & 
Braff, 1987). This disruption in PPI suggests a failure in sensorimotor gating that may 
result from stimulus over-flow either from the external environment and/or from within 
the subject itself.  
Mediating brain regions for PPI of the startle reflex are found mostly within the 
brain stem. Briefly, the acoustic prepulse is relayed from the inferior and superior 
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colliculus to the pedunculopontine tegmental nucleus, with lesser contributions to the 
circuit from the laterodorsal tegmental nucleus and substantia nigra, pars reticulata. 
Activation of the midbrain nuclei by the prepulse is converted into long-lasting inhibition 
of the giant neurons in the caudal pontine reticular nucleus, with the involvement of 
GABAB receptors contributing to the inhibition of the startle response (Fendt et al., 2001; 
Swerdlow et al., 2001). Other regions are shown to regulate the brain circuitry 
responsible for PPI, including the hippocampus and the prefrontal cortex, which have 
subcortical projections to the nucleus accumbens and ventral tegmentum (Swerdlow et 
al., 2001). Both NMDA and GABAB receptors contribute to this circuit and altering these 
receptors produces PPI deficits. This task is foundational as a preclinical behavioral test 
for animal models of schizophrenia.  
Another task used in research on animal models of schizophrenia to evaluate 
learning and memory deficits is the Morris water maze. Spatial learning and memory is 
disrupted in schizophrenic patients and it has been measured using a virtual, computer-
based water maze task (Folley et al., 2010; Hanlon et al., 2006). The original Morris 
water maze was developed for rodents and consists of a circular tank filled with opaque 
water and a submerged escape platform that is not visible. In order to locate the hidden 
platform using a spatial strategy, the animal must use spatial cues that are located outside 
the maze. Across days, control animals begin to utilize a spatial strategy that depends on 
the extra maze cues, which results in decreased latencies (time) to find the platform. To 
determine how well the animals learned the task, a probe trial is conducted in which the 
platform is removed and animals swim for a full trial period. Depending on how well 
they learned the task, the animals should spend most of their time in the area of the maze 
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where the platform was located. Performance in the water maze is disrupted after 
hippocampal lesions (Amaral & Witter, 1991; Moser, Moser, & Andersen, 1993) where 
both NMDA and GABAB receptors are prevalent (Dutar & Nicoll, 1988; Monaghan, 
Andaloro, & Skifter, 1998; Sakurai, Penney, & Young, 1993).  
Patients with schizophrenia exhibit deficits in emotional processing and emotional 
learning and memory (Hall et al., 2007). The deficits resemble those found in patients 
with amygdalae damage (Aleman et al., 2007; Hall et al., 2007; Kosaka et al., 2002; 
Whalley et al., 2009). For example, patients with schizophrenia have reduced activation 
of the amygdala when viewing emotional faces, as well as an alteration in hippocampal 
activity when viewing emotional scenes compared to control individuals (Hall et al., 
2007). Pavlovian fear conditioning is a type of associative learning task that has been 
utilized to test for deficits in emotional learning and memory in animal systems (Bolton 
et al., 2012; Kinney et al., 2002; Phillips & LeDoux, 1992). By pairing a neutral stimulus 
such as a tone (conditioned stimulus; CS) with one that elicits a fear response such as a 
mild foot shock (unconditioned stimulus; US), the CS will eventually elicit a similar fear 
response (freezing behavior in rodents) without the presence of the US. This association 
can be quantified using the fear response to the CS and serve as a measure of how well an 
animal learns the association. After training, the animal can be placed in a novel 
environment with the presentation of the original CS to determine the cued fear 
association (association of fear to the tone) or the animal can be placed in the original 
training environment with no CS presentations to demonstrate contextual fear association 
(association of fear to the environment). Different neural mechanisms and regions govern 
the associations utilized in this task depending on how the CS and US are presented 
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during training. In the standard delay cued and contextual fear (CCF) procedure, the CS 
and the US overlap in time and co-terminate. This training protocol requires amygdala 
activation to make the cued fear association (Davis & Whalen, 2001; Kinney et al., 2002; 
LeDoux et al., 1990; Phillips & LeDoux, 1992; Schafe et al., 2001) and the contextual 
fear association is dependent on the hippocampus (Chen et al., 1996; Holland & Bouton, 
1999; Kinney et al., 2002; Logue, Paylor, & Wehner, 1997; R. G. Phillips & LeDoux, 
1992). Manipulating the training protocol by inserting a temporal gap between the 
cessation of the CS and the onset of the US (trace CCF procedure) makes the task more 
difficult and more presentations of the CS and US are required to learn the association 
(Beylin et al., 2001; Kinney et al., 2002). Also, both the hippocampus and amygdala 
become imperative to make the cued fear association (Bolton et al., 2012; Kinney et al., 
2002; McEchron et al., 1998; 2000; Moyer, Deyo, & Disterhoft, 1990; Ryou, Cho, & 
Kim, 2001; Solomon et al., 1986; Sutherland & McDonald, 1990; Weiss et al., 1999) 
while contextual fear is still dependent on the hippocampus (Bolton et al., 2012; Chen et 
al., 1996; Holland & Bouton, 1999; Kinney et al., 2002; Logue et al., 1997; Phillips & 
LeDoux, 1992). Manipulations that result in differences in fear responses can reveal 
deficits in the mechanisms associated with different brain regions.  
The above behavioral tasks are used to measure learning and memory deficits in 
rodents with relevance to those observed in the schizophrenia population. NMDA 
receptor antagonists have been used in animal models to investigate symptoms associated 
with schizophrenia. As previously mentioned, these antagonists include PCP, ketamine, 
as well as MK-801. Although PCP produces more potent and longer lasting effects than 
the other NMDA antagonists, low doses of ketamine (subanesthetic doses) induce 
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changes in cortical GABAergic activity that result in disinhibition (Behrens et al., 2007). 
Subanesthetic doses of ketamine in adult rodents produce sensorimotor gating deficits as 
measured by PPI (Bolton et al., 2012; Braff & Geyer, 1990; Sabbagh et al., 2012), as well 
as behavioral alterations in the Morris water maze (Becker et al., 2003; Moosavi et al., 
2012; Sabbagh et al., 2012), and CCF (Bolton et al., 2012). Since blocking NMDA 
receptors on GABAergic interneurons produces a reduction in GABAergic tone due to 
diminished firing, an alternative approach to achieve a similar effect would be to alter 
GABA receptor function. As opposed to GABAA receptors whose responses are short 
lived, GABAB receptors provide the long lasting inhibition seen in oscillatory activity. 
However, drugs that target GABAB receptors are less utilized in schizophrenia research 
compared to NMDA receptor antagonists. As mentioned previously, GABAB receptor 
ligands administered to animals results in inconsistent behavior in learning and memory 
tasks (Myhrer, 2003). These inconsistencies may result because GABAB receptors are 
located pre, post, and extrasynaptically; further, the effect of the ligands may also rely on 
the task utilized. Our laboratory has demonstrated that administering a GABAB receptor 
agonist (baclofen) produces deficits in CCF (Heaney et al., 2012), and preliminary data 
suggest PPI deficits. While this approach to modeling schizophrenia has been productive 
in demonstrating potential mechanisms involved in the disorder, one drawback is that 
these deficits are only present when the drug is active in the animal’s system. Therefore, 
it may be relevant to determine if alterations during development produce similar deficits 
without administering drugs at the time of behavioral testing. 
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Neurodevelopmental Approaches 
Based on the typical age of diagnosis of schizophrenia and the overlap of this time 
point with several developmental processes, schizophrenia is suggested to be the result of 
disturbances in early brain development. Multiple proposed models argue that a change 
in developmental trajectory results in schizophrenia, which is not evident until early 
adulthood (Fatemi & Folsom, 2009; Lewis & Levitt, 2002; Lewis et al., 2004; Rapoport 
et al., 2005; Weinberger, 1987; Weinberger & Lipska, 1995). Studies that support this 
approach focus on post-mortem tissue analysis of patients with schizophrenia and the 
genetic and/or environmental stressors. 
Post-mortem tissue analysis reveals that there are changes in specific circuits in the 
brain related to subtle variations during development. These investigations have found 
cytoarchitectural disorganization in the hippocampus with too few neurons in the 
superficial layers and too many neurons in deeper layers (Jakob & Beckmann, 1986). 
This study has since been replicated using similar methodology and extended into the 
prefrontal, temporal, and limbic cortices with the same results (Akbarian et al., 1996; 
Arnold et al., 1991; Benes et al., 1991). This cytoarchitectural disorganization suggests a 
failure of neuronal migration and inappropriate final placement of neurons, an event that 
occurs during early development. In normal brain development, the migration of neurons 
to these regions occurs during the second trimester of intrauterine development (Rakic, 
1988). The disorganization of this process could potentially result in altered connectivity 
of these regions. Additionally, other post-mortem studies of patients with schizophrenia 
indicate there are no signs of neuronal damage (Falkai & Bogerts, 1986) and no sign of 
progressive worsening of the pathology over time, indicating that the cytoarchitecture 
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disorganization in schizophrenic patients must occur during development (Weinberger, 
1987; Weinberger & Lipska, 1995). The cause of the alterations in post-mortem tissue is 
not known but several potential mechanisms have been proposed.  
The initial disturbances during development might be triggered by a combination of 
genetic and/or environmental stressors. A number of susceptibility genes are associated 
with schizophrenia. For instance, the gene that encodes for the protein Reelin is reduced 
in the brains of patients with schizophrenia (Beffert et al., 2005; Impagnatiello et al., 
1998). Evidence from animal studies shows that an appropriate amount of Reelin is 
necessary for proper neuronal migration (Fatemi et al., 1999; Goffinet, 1979), and a 
reduced amount of Reelin results in cytoarchitectural alterations similar to what is seen in 
schizophrenic patients (Fatemi, 2005). Additionally, the transcription factor Lhx6 is 
reduced in post-mortem schizophrenia brains (Volk et al., 2012). Lhx6 is specific to cells 
that are destined to be PV+ neurons and, during the prenatal period, it participates in the 
regulation of cell type specification, tangential migration, and maturation of these 
specific PV+ GABAergic neurons (Liodis et al., 2007; Volk et al., 2012; Zhao et al., 
2008). Reduced Lhx6 in schizophrenic patients might explain the failure of PV+ neurons 
to appropriately express their phenotype. Changes in the expression of Reelin and Lhx6 
in schizophrenia patients provide support for a developmental origin of the disorder.   
 Genetic factors may make the system more susceptible to stressors, but they do not 
guarantee that one will inherit the disorder. Monozygotic twin studies indicate that there 
is only a 40-48% chance of one twin being diagnosed with schizophrenia if the other is 
already diagnosed (Suddath et al., 1990). These data indicate that although a genetic 
disposition to the disorder exists, there are environmental risk factors that also contribute 
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to the disease. Some environmental stressors that have been suggested to be involved in 
changing the developmental trajectory include maternal stress and infection, prenatal 
malnutrition, obstetric complications, and urban living (McNeil & Kaij, 1978; McNeil, 
1987; Vassos et al., 2012). Several large epidemiological studies indicate that prenatal 
exposure to viral infection increases the risk of schizophrenia due to the activation of the 
maternal immune response (Adams et al., 1993; Izumoto, Inoue, & Yasuda, 1999; 
Mednick, Huttunen, & Machon, 1994; Zuckerman et al., 2003). Stress in early life has 
been shown to produce behavioral differences in adult individuals and is complemented 
with data from rodent studies in laboratory settings (Gutman & Nemeroff, 2002). 
Although these studies inflict stress upon the developing fetus, the mechanism by which 
this would influence cytoarchitecture and molecular changes in the brain consistent with 
schizophrenia is not known.    
Development of the brain relies on the tightly regulated processes wherein the 
coordinated activity of various mechanisms is essential. NMDA receptor-mediated 
synaptic activity is necessary for normal development of various brain regions, as well as 
for coordinated network activity due to their involvement in critical processes such as 
establishing synaptic contacts, neuronal migration, and synaptogenesis (Contestabile, 
2000; Komuro & Rakic, 1993; LoTurco et al., 1991). However, GABA signaling 
precedes the development of NMDA receptor-mediated signaling and GABA plays a 
pivotal role in normal brain development as well. In early brain development, GABA 
acting on ionotropic GABAA receptors produces an excitatory, not inhibitory, response 
both in vitro and in vivo (Ben-Ari, 2007; Leinekugel et al., 2002; Sipila et al., 2006). This 
excitatory response is due to elevated intracellular chloride concentration in immature 
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neurons that begins to reduce to what is normally seen in mature cells around PND 5-7 in 
rodent pups and the effect of GABA acting on GABAA receptors becomes inhibitory 
around PND 10 (Ben-Ari et al., 1989; Ben-Ari et al., 2007). The early excitation provided 
by GABAA receptors aids in the membrane depolarization needed for NMDA receptors 
to expel the Mg2+ ion in order for the channel to be functional (Ben-Ari et al., 2007; Ben-
Ari et al., 1997). Presynaptic GABAB receptors are functional at birth and provide 
inhibitory control of neonatal network activity at this early stage in development (Ben-
Ari et al., 1997; McLean et al., 1996). Meanwhile, electrophysiological studies 
demonstrate that postsynaptic GABAB receptors on either pyramidal cells or interneurons 
are not functional during this time period (Caillard et al., 1998; Gaiarsa et al., 1995; 
Nurse & Lacille, 1999; Verheugen, Fricker, & Miles, 1999). Embryonic and neonatal rat 
hippocampal and cortical neurons do not exhibit postsynaptic GABAB receptor-mediated 
responses (the activation of potassium and the inhibition of Ca2+ currents) until after PND 
7 (Ben-Ari et al., 1997) due to the lack of coupling between the receptors and the ion 
channels (via G-proteins) (Fukuda, Mody, & Princa, 1993). The balance between 
excitation and inhibition during early brain development is vital for normal neuronal 
network formation.  
Since NMDA receptor activation is vitally important in development, and post-
mortem analyses point to alterations during critical periods associated with 
schizophrenia, studies have combined these theories by administering NMDA receptor 
antagonists to rodent pups during development to evaluate if deficits consistent with 
schizophrenia are produced. The first two weeks of life for a rat pup (especially at PND 
day 7) are a vulnerable period of brain development that correlates with the second 
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trimester of pregnancy in humans (See Figure 1 below; Bayer et al., 1993; Clancy, 
Darlington, & Finlay, 2001; Clancy et al., 2007). Studies have found that administering 
NMDA receptor antagonists (PCP, MK-801, and few using ketamine) during early stages 
of brain development in rodents (PND 7-14) results in an increase of neurodegeneration 
in brain areas implicated in schizophrenia and that this neurodegeneration is consistent 
with normal apoptosis that occurs during development and, therefore, is not related to 
excitotoxicity (Ikonomidou et al., 1999; Wang et al., 2001; Wang & Johnson, 2005). As 
mentioned, neurodegeneration and excitotoxic effects are not seen in post-mortem 
analyses of schizophrenic patients. Additionally, studies have found behavioral deficits in 
adult rats that had previously been administered NMDA receptor antagonists during the 
first weeks of postnatal life (see Figure 1 below). These studies demonstrate deficits in 
sensorimotor gating and PPI, consistent with schizophrenia-like symptoms (Abekawa et 
al., 2011; Anastasio & Johnson, 2008; Beninger et al., 2002; Broberg et al., 2010; Harris 
et al., 2003; Rasmussen et al., 2007; Turner et al., 2010; Van den Buuse, Garner, & Koch, 
2003; Wang et al., 2001; Wang & Johnson, 2005), with few using other behavioral tasks 
(Andersen & Pouzet, 2004). However, these previous studies use a moderate to high dose 
of drug that could possibly mimic a very large shutdown of the NMDA receptor system. 
It would be interesting to see if the effect of NMDA receptor antagonists administered at 
low doses produces similar learning and memory deficits in adulthood.    
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Figure 1. A comparison of rat and human brain development with a timeline of methods 
used in developmental approaches to schizophrenia. Derived from Tseng et al., 2009. 
 
The use of ketamine compared to other NMDA receptor antagonists in schizophrenia 
research has advantages. It is commonly used in veterinary medicine (and to some extent, 
pediatrics) as a dissociative anesthetic; however, at subanesthetic doses, it displays 
different properties. Compared to the other NMDA receptor antagonists, ketamine has a 
lower potency, a shorter duration of action, a faster rate of induction, and is effective 
across different animal species (Hevers et al., 2008). In our laboratory, the administration 
of ketamine in adult systems has proven to model deficits seen in schizophrenia for 
several behavioral tasks such as PPI, the Morris water maze, and trace CCF (Bolton et al., 
2012; Sabbagh et al., 2012). These features allow researchers to have better control of the 
drug in vivo, making it the optimal choice as an NMDA receptor antagonist. However, its 
utility at low doses in development to model deficits seen in schizophrenia has yet to be 
elucidated.     
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A more puzzling question in schizophrenia research is the effects of 
pharmacologically altering the GABAB receptor system in development. There has not 
yet been a study that examines administration of a GABAB receptor antagonist or agonist 
during development. Since NMDA receptors are centrally involved in the developmental 
pathogenesis of schizophrenia and rely on GABAB receptors during development, it is 
unknown what may occur if the GABAB receptor system is altered during this stage. As 
previously discussed, GABABR1 knockout mice display massive behavioral impairments, 
die prematurely, and may be a better model for epilepsy than schizophrenia (Prosser et 
al., 2001; Schuler et al., 2001). However, disturbing the GABAB receptors either by 
enhancing or inhibiting their function intermittingly could provide valuable insight into 
their role as it relates to this disorder.  
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Hypotheses and Implications 
 Building upon the wealth of research that implicates altered function of the 
NMDA receptor and changes in GABAergic signaling in schizophrenia as well as the 
importance of their role in brain development, we examined the behavioral and 
biochemical consequences of disrupting the functioning of either NMDA or GABAB 
receptors during critical time points in development. 
 Hypothesis 1:  
We administered the NMDA receptor antagonist ketamine at a low dose (8 
mg/kg) to rat pups at PND 7, 9, and 12. In adulthood, the animals should exhibit 
sensorimotor gating deficits measured by a reduction in PPI, impairments in 
spatial learning and memory demonstrated by the Morris water maze task, and 
deficits in fear associative learning seen in trace CCF compared to controls. The 
examination of brain tissue should result in alterations of proteins associated with 
NMDA receptors, GABA receptors, and GAD67, all of which have been found to 
be disrupted in schizophrenia.   
  Implications of Hypothesis 1: 
If the low dose ketamine administration during development produces 
behavioral and protein expression changes consistent with what is 
observed in other schizophrenia models, then the data would indicate that 
alterations in NMDA receptors at the specific time points (PND 7, 9, and 
12) induce a change in the system that results in deficits consistent with 
the disorder. Alternatively, if the dose and schedule of ketamine 
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administration does not induce the proposed deficits, it may be possible 
that a subtle, transient blockade of this receptor system is not enough to 
disrupt the developing network system and an increase in dose or multiple 
injection days may be considered.     
 Hypothesis 2: 
In addition to the administration of ketamine to post-natal rat pups, we 
administered the GABAB receptor antagonist phaclofen and the GABAB receptor 
agonist baclofen to different groups of animals. The injections were on PND 7, 9, 
and 12 to determine if a change in GABAergic signaling during critical periods 
produces changes in behavior. There is a delicate balance in GABA signaling 
during development (as previously demonstrated) so the present study will 
determine if blocking or enhancing GABAB receptor function during this 
developmental period alters behavior in adulthood. We hypothesized that 
phaclofen and baclofen, each, would produce behavioral deficits (reductions in 
PPI and deficits in the Morris water maze and trace CCF) similar to ketamine 
deficits in Hypothesis 1. Blocking (with phaclofen) or enhancing (with baclofen) 
theoretically would alter connections in the developing brain and change network 
function. We also proposed that the tissue analyses would indicate alterations in 
proteins related to the GABAergic signaling.  
 Implications of Hypothesis 2: 
If altering GABAB receptors, either by reducing or enhancing their 
function, during early brain development produces behavioral and/or 
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protein changes similar to what is seen in schizophrenia, then this 
experiment will provide evidence for the involvement of GABA signaling 
dysfunction potentially being involved in the disorder. If no deficits are 
detected with either phaclofen or baclofen, then alternate dosages and 
schedule of administration would be useful. The possibility exists that 
direct alterations of GABAB receptor function alone may be insufficient to 
alter developmental trajectories.  
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CHAPTER 3 
MATERIALS AND METHODS 
Subjects 
 Eight timed pregnant Sprague-Dawley dams were obtained from Charles River 
Laboratories (Hollister, CA). Dams were individually housed until parturition with a 12 
hour light/dark cycle and with food and water available ad libitum. The day of birth was 
considered PND 0. Pups were sexed and randomly assigned to one of four treatment 
groups (saline, ketamine, baclofen, or phaclofen) on PND 2. All pups were weaned on 
PND 21 and pair housed throughout the remainder of the experiment with male (n = 55) 
and female (n = 35) animals housed in separate colony rooms. Behavioral testing began 
on PND 60 which corresponds to brain maturity in early adulthood for humans (Pignatelli 
et al., 2006). All procedures were performed in accordance with NIH guidelines for 
ethical treatment of research subjects, and approved by the University of Nevada, Las 
Vegas Animal Care and Use Committee. 
Drug Treatments 
   All drugs were mixed with physiological saline (0.9% NaCl) to achieve a final 
concentration of 8 mg/ml ketamine (ketamine HCL from Henry-Schein, Indianapolis, 
IN), 2 mg/ml baclofen (baclofen hydrochloride from Sigma-Aldrich, St. Louis, MO), 0.3 
mg/ml phaclofen (from Sigma-Aldrich, St. Louis, MO). The drugs were administered 
subcutaneously (SC) at a dose of 1 ml/kg. Animals were randomly assigned one of the 
three treatment groups: saline (n = 14 males; n = 6 females), ketamine (n = 14 males, n = 
10 females), baclofen (n = 14 males; n = 9 females), and phaclofen (n = 13 males; n = 10 
females). 
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Apparatus 
Prepulse Inhibition of Acoustic Startle  
 Acoustic startle chambers (San Diego Instruments, San Diego, CA) measuring 28 
cm (W) x 28 cm (H) x 28 cm (L) were used for the acoustic startle and PPI. Inside the 
chamber, the animals were individually placed in a transparent Plexiglas tube (10 cm 
wide and 20 cm long) that is mounted on an accelerometer which measures changes in 
movement. A Cobalt Instruments computer using Acoustic Startle software package 
(Startle, San Diego Instruments) recorded the data from the accelerometer.     
Fear Conditioning Chambers 
 A Freeze Monitor chamber (San Diego Instruments) measuring 25.4 cm (W) x 
19.05 cm (H) x 25.4 cm (L) with a stainless steel grid floor and Plexiglas walls was used 
to perform both the fear conditioning training and contextual fear test. The chamber was 
cleaned with Formula 409 (Chlorox, Oakland, CA) solution at the end of each session. 
An altered context chamber was used to test cued fear. This chamber consisted of an 
opaque plastic enclosure measuring 12.7 cm (W) x 26.67 cm (H) x 43.18 cm (L) with the 
addition of a vanilla scent on an inner wall to ensure a different olfactory background for 
the altered context. A solution of 0.1% ethanol was used to clean the chamber after each 
session. The chambers were connected to a Cobalt Instruments computer with the Freeze 
Monitor software (San Diego Instruments) to run each session. Freezing behavior (no 
movement besides breathing) was recorded every 10 seconds.  
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Morris Water Maze 
 The Morris water maze procedure was performed in a white polyethylene circular 
tank, 1.8 m (diameter), 76 cm (H), and 4.7 mm in thickness (San Diego Instruments). The 
tank was filled with tap water 48 cm deep and maintained at 25˚C. The addition of non-
toxic paint made the water opaque to conceal the hidden platform (10 cm x 10 cm square 
platform made of clear plastic). The tank was divided into four quadrants, one in which 
the hidden platform was placed in the center 30 cm from inside the wall of the tank and 
1.5 cm below the surface of the water. A 13 cm x 13 cm square white plastic cover, 
protruding 3 cm above the water, was placed on top of the platform during the visible 
training trials. The tank was positioned in the center of a training room (separate from the 
colony room) with large geometric shapes positioned on all four walls to serve as distal 
spatial cues for the animals to find the hidden platform. Trials were recorded and 
captured using a video tracking system (Smart, San Diego Instruments) from a Sony 
Handycam camera connected to a Cobalt Instruments computer. Latency to locate the 
hidden platform, speed of swimming, and thigmotaxis (proportion of time spend along 
the outer edge of the maze) data was collected for each trial. The amount of time subjects 
spent in each quadrant was recorded for the probe trial. 
Tail Flick  
 The tail flick procedure was performed using a circular glass bowl, 20.32 cm 
(diameter) and 7.62 cm (H), filled with 1800 ml of water. The bowl was placed on a 
heating plate to maintain the water at 55˚C throughout each session.   
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Drug Administration 
 After the pups were sexed and randomly assigned to treatment groups on PND 2, 
they received 1 ml/kg subcutaneous injection of saline, ketamine, baclofen, or phaclofen 
on PND 7, 9, and 12 (Figure 1) then weighed every day until weaning (PND 21) to 
ensure proper growth and development.  
Behavioral Testing 
All behavioral testing began once animals reached PND 60 to ensure they reached 
early adulthood. All experimenters were blind to the subject’s treatment group throughout 
testing.  
Prepulse Inhibition of Acoustic Startle  
 Animals were taken into a separate training room and individually placed in the 
startle chambers. Animals were given five minutes to acclimate to the environment and 
presented with background noise (65 dB) throughout the session. Acoustic startle 
responses were examined after the presentation of 30 ms noise bursts of 90, 100, 110, and 
120 dB. Sensorimotor gating was tested with auditory white noise prepulses of 74, 82, 86, 
or 90 dB presented 40 ms or 100 ms prior to the 120 dB startle pulse. Inter-trial intervals 
were randomized between 10 and 55 seconds. For each session, a random order of trial 
type presentations was presented 5 times. When evaluating the acoustic startle data, the 
first trial of each acoustic startle intensity response was discarded and averages of the 
remaining four trials were used for calculation. Percent PPI was calculated using the 
following equation: 100-[(average startle response with pre-pulse)/(average acoustic 
startle)]*100.   
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Cued and Contextual Fear Conditioning (CCF) 
 Subjects were individually taken from the colony room and placed in the fear 
conditioning chamber located in a separate training room. The animals were allowed to 
freely explore the chamber during the initial two minutes of the training session in which 
no stimuli were presented. Following the initial two minutes in the chamber, a 2.9 kHz 88 
dB tone conditioned stimulus (CS) was presented for 30 s; 2.5 s following the termination 
of the CS, a 1 second 0.5 mA footshock (US) was administered. Following the 
termination of the US, a two minute interval elapsed prior to the next CS and US 
presentation. A total of 4 CS-US pairings were presented in the training session, each 
separated by two minute intervals. After the completion of the last pairing, the animals’ 
behavior was observed for a final two minutes. The animals’ freezing behavior was 
evaluated every ten seconds throughout the session by a trained experimenter blind to the 
experimental group. The criterion for freezing consisted of no movement of the animal 
other than breathing. Freezing behavior was recorded during the training session for the 
first two minutes (pre-training freezing) and for the final two minutes (post-training). 
Once the session was complete, the animal was returned to its home cage in the colony 
room and the chamber was cleaned.  
 Cued fear testing (fear to the CS) was examined 24 hours after training. Animals 
were individually placed in the altered context for a total of 13 minutes. The session 
consisted of an initial two minute interval, during which no stimuli were presented in 
order to evaluate freezing to the novel environment. A one minute presentation of the 
original CS used in training was presented, followed by a two minute interval between 
the onsets of the next CS tone, for a total of 4 CS tone presentations. Freezing behavior 
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was measured throughout the entire session. The animals were brought back to their 
home cage following the completion of the session and the chamber was thoroughly 
cleaned with 0.1% ethanol.   
 Contextual fear (fear to the training environment) was tested 48 hours after 
training. Animals were placed in the initial training chamber and allowed to freely 
explore for 10 minutes without any CS or US presentations. Freezing behavior was 
measured during the entire session in five, 2 minute bins. After the session, the animals 
were returned to their home cage and the chamber was cleaned.   
 A cued fear session (72 hours after training) and contextual fear session (96 hours 
after training) were administered in an identical fashion as previously described 
following the 48 hour contextual test. However, following the 96 hour contextual fear 
session, one CS-US pairing was presented (reminder trial) followed by a final two minute 
period of observation. An additional cued fear session (24 hours after reminder) and 
contextual fear session (48 hours after reminder) was carried out on subsequent days 
using the same protocols detailed above.     
Morris Water Maze 
 Individually, animals were taken from the colony room into a separate testing 
room. A computer desk, a table with a heating cage, large geometric shapes on each wall, 
and the experimenter served as distal spatial cues as they can be seen from inside the 
maze. The animal was placed into the maze and into the water along the outer wall of one 
of the three randomly chosen quadrants that do not contain the hidden platform. The 
animal was allowed to swim until locating the hidden platform or for a maximum of 60 
seconds. After 60 seconds, the experimenter guided the animal to the hidden platform. 
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Each animal was given 20 seconds to sit/stand on the platform to allow spatial orientation 
to distal extra-maze cues after which they were taken out of the maze and placed in a 
holding cage under a heat lamp for 30 seconds. Three additional trials were conducted 
using the same protocol for a total of four training trials per day. After the fourth interval 
under the heating lamp, the animal was gently dried with a towel and taken back to its 
home cage. The platform remained in the same location for each trial and across days. 
Training trials were conducted on successive days until the completion of either six days 
of hidden platform training or until the controls reached a latency of ≤ 15 seconds. The 
animals’ path, latency, thigmotaxis, swim speed, and quadrant location was recorded.   
 Once the control animals reached the hidden platform latency criterion, a single 
probe trial was performed the following day. The hidden platform was removed from the 
maze and the animal was allowed to swim for 60 seconds with the tracking system 
measuring the amount of time the animal spent in each quadrant. To examine the ability 
of how well the animals learn a new location of the hidden platform, a reversal procedure 
was used in which the platform was moved to the opposite quadrant (180 degrees from 
original location) and the animals were given four trials with the same protocol as a 
hidden platform day. To test for visual and motor capabilities, a non-spatial test was 
performed using a visible platform. This task is similar to the hidden platform protocol 
except that the platform is visible to the animal and moved on successive trials to 
different quadrants for each trial.       
Tail Flick 
 In order to ensure any differences that may be observed during the fear 
conditioning procedure are not tied to changes in nociception (i.e. analgesia), a standard 
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tail flick nociception test was performed on all animals. Subjects were individually taken 
from their home cage into a testing room. The initial 2–3 centimeters of the tip of the tail 
was placed in 55º C water and the latency for the animal to flick its tail out of the water 
was recorded. A maximum of 10 seconds was set as a criterion for withdrawal (flick). 
Tissue Analysis 
Tissue Collection 
 Following the tail flick test, all animals were humanely euthanized using CO2 
asphyxiation. Brains were immediately removed following CO2 asphyxiation. The frontal 
portion of the cortex was dissected out, placed in microcentrifuge tubes, and kept frozen 
at -80˚C until tissue homogenization.    
SDS-PAGE Western Blotting 
 Prefrontal cortices were homogenized using a RIPA buffer (20 mM pH 7.5 Tris-
HCL, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% sodium deoxycholate, 2.5 mM 
sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin; 
Cell Signaling, Danvers, MA) with 1 mM DTT, 1 mM PMSF, 20µg/ml aprotinin, and 
0.1% SDS added. Homogenization was performed using a handheld Polytron 
(Kinematica Inc., Luzern, Switzerland) tissue homogenizer. Homogenized tissue was 
centrifuged for 15 minutes at 15,000 x g at 4˚C. Supernatant was removed without 
disturbing the pellet and a protein concentration assay was performed using the 
bicinchoninic acid assay (BCA, Pierce, Rockford, IL). 
 Protein samples were loaded into 10% acryl gels at a concentration of 2 µg/µl 
with a mixture of Laemmeli buffer containing 2% SDS (BioRad, Hercules, CA) and DI 
water for a total of 10 µL volume. SDS-PAGE was held at a constant current 0.04 A for 
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45 minutes to separate protein samples according to molecular weight. Following the 
separation, the proteins were electrotransferred at 0.25 A for 1 hour to 0.2 µm 
nitrocellulose membranes (GE Water and Process Technologies, Feasterville-Trevose, 
PA). Membranes were placed in a blocking buffer with 5% BSA and TBST (1x Tris-
buffered saline with 0.05% Tween 20) before being incubated overnight at 4˚C in 
primary antibody (anti-GABAAα5 polyclonal rabbit, 1:750 (Millipore, Billerica, MA); 
anti-GABAB1 polyclonal rabbit, 1:2000 (Cell Signaling Technology, Danvers, MA); anti-
GABAB2 polyclonal rabbit, 1:1000 (Cell Signaling Technology); anti-GAT1 polyclonal 
rabbit 1:1000 (Cell Signaling Technology); anti-NR2B polycolonal rabbit 1:100 (Cell 
Signaling Technology); anti-Kalirin polyclonal rabbit, 1:1000 (Cell Signaling 
Technology); anti-β-Actin monoclonal rabbit, 1:20,000 (ProteinTech, Chicago, IL)). 
Membranes were returned to room temperature the following day and washed with TBST 
3 times for 10 minutes each. Following washes, membranes were incubated in secondary 
antibody (HRP-conjugated anti-rabbit, 1:5000, Vector Laboratories, Burlingame, CA) for 
1.5 hours at room temperature. Following 3 additional 10 minute washes with TBST, the 
membranes were exposed to Amersham ECL Plus detection system (GE Healthcare Life 
Sciences, Pittsburgh, PA) and imaged using a Typhoon 9410 Variable Mode Imager (GE 
Healthcare Life Sciences). ImageQuant 5.2 software (GE Healthcare Life Sciences) was 
used to determine protein quantities. The proteins of interest were normalized to β-Actin 
density. The treatment group’s normalized values were compared to the average control 
(saline) normalized values for each membrane. All SDS-PAGE experiments were all run 
in duplicate to ensure consistent data.   
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Statistical Analysis 
  Acoustic startle response and PPI data were analyzed via repeated measures 
analysis of variance (RM-ANOVA) across startle or prepulse intensities. One-way 
ANOVA for individual startle and prepulse intensities were performed after a significant 
RM-ANOVA. Mean latencies, swim speed, and thigmotaxis from the water maze for 
hidden platform days were analyzed across days using RM-ANOVA. Data from the time 
spent in each quadrant during the probe trial in the water maze were analyzed using one-
way ANOVA (target versus other quadrants). RM-ANOVA were used for the CCF data 
except one-way ANOVA were used to determine differences between treatment groups 
in pre CS-US freezing and post CS-US freezing on the training day. Mean latencies for 
tail flick and mean densities for western blotting were analyzed using one-way ANOVA. 
Tukey post-hocs were performed following a significant ANOVA. To parse out the 
differences between the control group and either ketamine or the GABAB ligands, 
separate analyses were conducted. Males and females were analyzed separately except 
when comparing males versus females for the GAD67 protein.   
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CHAPTER 4 
RESULTS 
Behavioral Testing 
Prepulse Inhibition of Acoustic Startle  
 A significant difference was observed in acoustic startle response (Figure 2) 
between treatment groups for the male animals (RM-ANOVA; F(3,216) = 3.425, p = 
0.018). The baclofen group exhibited a significant increase in startle response compared 
to saline (Tukey post hoc; p = 0.013). Analysis of individual startle intensities revealed 
that the significant increase in acoustic startle for the baclofen group occurred at 100 dB 
(One-way ANOVA; F(3,216) = 5.212, p = 0.002; Tukey post hoc: baclofen versus saline, p 
= 0.020) and 110 dB (One-way ANOVA; F(3,216) = 4.842, p = 0.003; Tukey post hoc: 
baclofen versus saline, p = 0.002) but not at 120 dB compared to saline. Conversely, 
significant reductions in startle responses were observed between the female treatment 
groups compared to saline (RM-ANOVA; F(3,136) = 6.942, p = 0.000). The baclofen and 
phaclofen treated groups displayed a significant decrease in acoustic startle response 
compared to saline (Tukey post hoc: baclofen versus saline, p 0.019; phaclofen versus 
saline, p = 0.009). The decrease in acoustic startle response occurred at the 120 dB 
intensity (One-way ANOVA; F(3,136) = 5.920, p = 0.001; Tukey post hoc: baclofen versus 
saline, p = 0.010; phaclofen versus saline, p = 0.004). 
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Figure 2. Acoustic Startle Responses. Mean startle amplitudes (±SEM) in response to 
noise bursts at multiple decibel intensities for males and females. Baclofen treated males 
exhibited a significant increase in startle response while the baclofen and phaclofen 
treated females displayed a significant reduced startle response. * = Significantly 
different from saline, p < 0.05.  
 For the PPI trials with a 100 ms inter-stimulus interval (ISI; Figure 3), no 
significant differences were observed between treatment groups compared to controls for 
the male animals across all prepulse intensities (RM-ANOVA; F(3,216) = 2.268, p = 
0.082). However, the female animals displayed a significant difference between treatment 
groups compared to controls (RM-ANOVA; F(3,136) = 8.586, p = 0.000). Across prepulse 
intensities, the female baclofen group (Tukey post hoc, p = 0.006) and phaclofen group 
(Tukey post hoc, p = 0.000) exhibited a significant reduction in PPI. These reductions 
were observed at all of the prepulse intensities except for the 86 dB prepulse (One-way 
ANOVA; 74 dB: F(3,136) = 4.058, p = 0.008, Tukey post hoc: baclofen versus saline, p = 
0.018, phaclofen versus saline, p = 0.010; 78 dB: F(3,136) = 5.066, p = 0.002, Tukey post 
hoc: balcofen versus saline, p = 0.015; phaclofen versus saline, p = 0.020; 82 dB: F(3,136) 
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= 4.354, p = 0.006, Tukey post hoc: phaclofen versus saline, p = 0.004; 90 dB: F(3,136) = 
3.571, p = 0.016, Tukey post hoc: phaclofen versus saline, p = 0.018)..  
Separate analyses were conducted to compare only the ketamine and saline 
groups for the PPI trials with 100 ms ISI (Figure 3). A significant reduction in PPI was 
observed between the ketamine treated female group versus the female controls across 
prepulse intensities (RM-ANOVA; F(1,62) = 8.313, p = 0.005), significant reductions were 
observed at the 74 (One-way ANOVA; F(1,62) = 7.525, p = 0.008) and 86 dB (F(1,62) = 
4.247, p = 0.044) prepulse intensities.  
 
Figure 3. Percent Prepulse Inhibition with 100 ms ISI. Mean percent PPI (±SEM) at 
multiple prepulse intensities preceding 120 dB startle stimulus. No differences observed 
between the male treatment groups while significant reductions in PPI were seen for the 
baclofen and phaclofen treated females. # = Significantly differently from saline 
(ketamine analyzed in isolation), p < 0.05. * = Significantly different from saline, p < 
0.05.  
 
 An evaluation of the PPI trials with a 40 ms ISI (Figure 4) revealed a significant 
difference between treatment groups across prepulse intensities in the male animals (RM-
ANOVA; F(3,161) = 3.931, p = 0.010). Post-hoc analyses revealed a significant reduction 
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in PPI in the phaclofen group (Tukey post hoc: phaclofen versus saline, p = 0.024). One-
way ANOVA for each prepulse intensity revealed a significant reduction only at the 74 
dB prepulse (F(3,161) = 2.930, p = 0.035; Tukey post hoc: phaclofen versus saline, p = 
0.039). Female animals demonstrated a similar significant reduction in PPI across 
prepulse intensities (F(3,101) = 9.843, p = 0.000) for the phaclofen group compared to 
saline (Tukey post hoc: p = 0.000). One-way ANOVA for individual prepulse intensities 
revealed the same significant reduction at the 74 dB prepulse intensity (F(3,101) = 5.439, p 
= 0.002; Tukey post hoc: phaclofen versus saline, p = 0.006), 86 (F(3,101) = 4.322, p = 
0.007; Tukey post hoc: phaclofen versus saline, p = 0.010), as well as a significant 
difference at the 90 dB prepulse (F(3,101) = 3.145, p = 0.028; Tukey post hoc: phaclofen 
versus saline, p = 0.045).  
 
Figure 4. Percent Prepulse Inhibition with 40 ms ISI. Mean percent PPI (±SEM) at 
multiple prepulse intensities preceding 120 dB startle stimulus. Significant reductions in 
PPI were observed across prepulse intensities for both male and female phaclofen treated 
groups with a lack of PPI occurring at the 74 dB. * = Significantly different from saline, 
p < 0.05. 
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Cued and Contextual Fear Conditioning  
 No significant differences were observed in the freezing behavior of the males 
throughout training on Day 1 (see Figure 5). All groups froze equivalently during the two 
minute interval before the onset of the CS-US pairings (Pre CS-US; F(3,51) = 0.709, p = 
0.551) and during the two minute interval after the last CS-US pairings (Post CS-US; 
F(3,51) = 0.696, p = 0.559). Similarly, the female animals were equivalent in their freezing 
behavior between groups during the Pre CS-US (F(3,31) = 0.908, p = 0.448) and Post CS-
US (F(3,31) = 0.536, p = 0.661) as shown in Figure 5.  
 
Figure 5. Day 1 CCF Training. Proportion of time freezing (±SEM) was determined for 
the first two minutes of training (Pre CS-US) and the last two minutes of training (Post 
CS-US) for the males and females. No differences were observed between treatment 
groups.  
 Following training, fear to the CS in a novel environment (cued fear) was tested 
(Cued Fear Day 2; Figure 6a). No differences were observed between the male treatment 
groups in freezing behavior during the first two minutes of the cued fear session (Pre 
CS1; F(3,51) = 0.985, p = 0.407) and during the presentation of the cues (RM-ANOVA 
across CS1-CS4; F(3,51) = 0.767, p = 0.518). The female animals also displayed no 
differences in freezing between treatment groups during Pre CS1 (F(3,31) = 2.847, p = 
0.054) and similar freezing behavior during cue presentations (RM-ANOVA across CS1-
CS4; F(3,31) = 1.897, p = 0.151).  
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Freezing to the training environment on (contextual fear) on Day 3 (Figure 6b) 
revealed no differences between the male treatment groups across the entire session (RM-
ANOVA across Blocks 1-5; F(3,51) = 0.204, p = 0.893) and, consistent with the males, no 
differences were observed for the female animals  (RM-ANOVA across Blocks 1-5; 
F(3,31) = 2.626, p = 0.068).  
For Cued Fear Day 4 (Figure 7a), no significant differences were observed in 
freezing behavior between male treatment groups for Pre CS1 (F(3,51) = 0.885, p = 0.455) 
or across cue presentations (RM-ANOVA across CS1-CS4; F(3,51) = 0.348, p = 0.791). 
Female animals also displayed no significant differences between treatment groups for 
freezing behavior during Pre CS1 (F(3,31) = 0.670, p = 0.577) and across cue 
presentations(RM-ANOVA across CS1-CS4; F(3,31) = 0.989, p – 0.411). 
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Figure 6. Cued Fear Day 2 and Contextual Fear Day 3. Proportion time freezing (±SEM) 
was measured for Cued Fear Day 2 (a) during the first two minutes before the 
presentation of the cues (Pre CS1) and during the cue presentations (CS1-CS4) and for 
Contextual Fear Day 3 (b) during each 5 two minute blocks. No significant differences 
were observed between treatment groups.    
No differences in freezing were detected on Contextual Fear Day 5 (Figure 7b) 
between the male treatment groups (RM-ANOVA across Blocks 1-5; F(3,51) = 0.282, p = 
0.838) and female treatment groups (RM-ANOVA across Blocks 1-5; F(3,31) = 2.571, p = 
0.072) across the entire session. A single reminder trial (CS-US) was presented at the end 
of the session. During the two-minute interval following the reminder trial, neither male 
(F(3,51)  = 1.031, p = 0.387) nor female (F(3,31) = 0.369, p = 0.776) animals displayed 
differences in freezing behavior. 
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Figure 7. Cued Fear Day 4 and Contextual Fear Day 5. Proportion time freezing (±SEM) 
was measured for Cued Fear Day 4 (a) during the first two minutes before the 
presentation of the cues (Pre CS1) and during the cue presentations (CS1-CS4) and for 
Contextual Fear Day 5 (b) during each 5 two minute blocks. Freezing was measured 
during the cue presentation (Reminder) and the final two minutes after the CS-US 
presentation (Post Reminder).      
0
0.1
0.2
0.3
0.4
0.5
0.6
Pre CS1 CS1 CS2 CS3 CS4 Pre CS1 CS1 CS2 CS3 CS4
Males Females
Pr
o
po
rt
io
n
 
o
f T
im
e 
Fr
ee
zi
n
g
Portion of Session
Saline
Ketamine
Baclofen
Phaclofen
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Bl
o
ck
 
1
Bl
o
ck
 
2
Bl
o
ck
 
3
Bl
o
ck
 
4
Bl
o
ck
 
5
Re
m
in
de
r 
Po
st
 
Re
m
in
de
r 
Bl
o
ck
 
1
Bl
o
ck
 
2
Bl
o
ck
 
3
Bl
o
ck
 
4
Bl
o
ck
 
5
Re
m
in
de
r 
Po
st
 
Re
m
in
de
r 
Males Females
Pr
o
po
rt
io
n
 
o
f T
im
e 
Fr
ee
zi
n
g
Portion of Session (2 min each block)
Saline
Ketamine
Baclofen
Phaclofen
(a) 
 
 
 
 
 
 
 
(b) 
48 
 
 
Figure 8. Cued Fear Day 6 and Contextual Fear Day 7. Proportion time freezing (±SEM) 
was measured for Cued Fear Day 6 (a) during the first two minutes before the 
presentation of the cues (Pre CS1) and during the cue presentations (CS1-CS4). The 
phaclofen treated females displayed a significant decrease in freezing during the CS 
presentations. Proportion time freezing (±SEM) was measured for Contextual Fear Day 7 
(b) during each 5 two minute blocks. No differences between treatment groups were 
observed. * = Significantly different from saline, p < 0.05.    
Freezing behavior on Cued Fear Day 6 Post Reminder (Figure 8a) revealed no 
significant differences between treatment groups for the male animals for Pre CS1 (F(3,51) 
= 1.989, p = 0.127) and across cue presentations (RM-ANOVA across CS1-CS4; F(3,51) = 
1.263, p = 0.297). Although no significant differences among treatment groups in 
freezing behavior were seen for Pre CS1 for female animals (F(3,31) = 1.273, p = 0.301), 
the phaclofen group displayed a significant decrease in freezing across cue presentations 
(RM-ANOVA; F(3,31) = 3.012, p = 0.045; Tukey post hoc: phaclofen versus saline, p = 
0.028). One-way ANOVA revealed the significant reductions occurred during CS1 (F(3,31) 
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= 4.298, p = 0.012; Tukey post hoc: phaclofen versus saline, p = 0.006) and CS2 (F(3,31) = 
3.308, p = 0.033; Tukey post hoc: phaclofen versus saline, p = 0.026). 
 For Contextual Day 7 Post Reminder (Figure 8b), no significant differences were 
found for the male animals across the two minute blocks (RM-ANOVA across blocks; 
F(3,51) =  0.386, p = 0.764). Similarly, no significant differences in freezing were observed 
between treatment groups for the female animals (RM-ANOVA across blocks; F(3,31) = 
1.811, p = 0.166). 
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Morris Water Maze 
 Latency to reach the hidden platform across successive days was measured for six 
consecutive days (Figure 9a). No significant differences were observed in latency for 
males between treatment groups across hidden platform training (RM-ANOVA; F(3,215) = 
2.079, p = 0.104). Similarly, latencies between treatment groups for the female animals 
were not significantly different across days (RM-ANOVA; F(3,215) = 0.017, p = 0.997). 
Swim speed across hidden platform training days (Figure 10a) revealed no differences 
between the male treatment groups (RM-ANOVA; F(3,215) = 1.989, p = 0.117) and the 
female treatment groups (RM-ANOVA; F(3,79)  = 1.711, p = 0.172). However, 
thigmotaxis (proportion of time spent on the outer perimeter, Figure 10b) differed among 
the male treatment groups across hidden platform days (RM-ANOVA; F(3,215)  = 2.882, p 
= 0.037) with the ketamine group spending significantly more time along the perimeter 
(Tukey post hoc, p = 0.049). The female treatment groups displayed no differences in 
time spent along the perimeter across hidden platform days (RM-ANOVA; F(3,80)  = 
2.342, p = 0.079). Separate analyses were performed comparing only male ketamine 
group to the male saline group. The male ketamine group displayed a significantly 
increased latency to find the hidden platform over successive days (RM-ANOVA; F(1,38) 
= 6.883, p = 0.012). Swim speed was not significantly different between the male saline 
and ketamine groups (RM-ANOVA; F(1,109) = 0.063, p = 0.802), the ketamine group did 
display higher thigmotaxis (RM-ANOVA; F(1,109) = 7.141, p = 0.009) which could be 
related to the longer latency during the hidden trials.  
 After completion of the last day of hidden platform training, a probe trial was 
performed (Figure 9b). The baclofen treated males failed to display a selective search as 
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measured by time spent in target quadrant versus all other quadrants (F(3,51) = 4.493, p = 
0.007; Tukey post hoc: target versus quadrant 1, p = 0.118; target versus quadrant 2, p = 
0.043; target versus quadrant 3, p = 0.006 ). The male saline, ketamine, and phaclofen 
group each displayed a significant search during the probe trial (saline: F(3,55) = 15.015, p 
= 0.000; Tukey post hoc, target versus quadrant 1, p = 0.000; target versus quadrant 2, p 
= 0.000; target versus quadrant 3, p = 0.000; ketamine: F(3,55)  = 13.886, p = 0.000; Tukey 
post hoc, target versus quadrant 1, p = 0.008; target versus quadrant 2, p = 0.000; target 
versus quadrant 3, p = 0.000; phaclofen: F(3,51) = 11.176, p = 0.000; Tukey post hoc, 
target versus quadrant 1, p = 0.005; target versus quadrant 2, p = 0.000; target versus 
quadrant 3, p = 0.000). In the female animals, a selective search for the former platform 
location was observed for the baclofen (F(3,32) = 15.153, p = 0.000; Tukey post hoc target 
versus quadrant 1, p = 0.000; target versus quadrant 2, p = 0.000; target versus quadrant 
3, p = 0.000) and phaclofen (F(3,36) = 4.865, p = 0.006; Tukey post hoc target versus 
quadrant 1, p = 0.039; target versus quadrant 2, p = 0.008; target versus quadrant 3, p = 
0.027) treated female groups as measured by the proportion of time spent in the target 
quadrant.  The female saline and ketamine treatment groups did not exhibit a selective 
search, failing to spend significantly more time in any quadrant (saline: F(3,20) = 1.362, p = 
0.283; ketamine: F(3,36) = 1.466, p = 0.240).  
 Reversal training was carried out 24 hours following the probe trial. Neither the 
males nor female animals displayed any significant differences in latency to find the new 
platform location (Figure 9a; Males: F(3,215) = 1.079, p = 0.359; Females: F(3,136) = 0.767, 
p = 0.514) or swim speed differences (Figure 10a; Males: F(3,215) = 0.734, p = 0.533; 
Females: F(3,135) = 1.740, p = 0.162). However, the ketamine treated male group exhibited 
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a significant increase in thigmotaxis compared to the control group (Figure 10b; F(3,215) = 
4.621, p = 0.04; Tukey post hoc saline versus ketamine, p = 0.010). No significant 
differences in thigmotaxis were observed between the female treatment groups (Figure 
10b; F(3,136) = 1.527, p = 0.210).  
Visible platform training was conducted to assess visuomotor abilities. Significant 
differences were found among the male treatment groups for latency to locate the visible 
platform (Figure 9a; RM-ANOVA; F(3,215) = 3.039, p = 0.030); however, no significant 
differences between groups were detected in post hoc analyses  (Tukey post hoc; saline 
versus ketamine, p = 0.927; saline versus baclofen, p = 0.991; saline versus phaclofen, p 
= 0.069). While no differences were observed between the male treatment groups for 
swim speed (Figure 10a; RM-ANOVA; F(3,215) = 0.817, p = 0.457), the ketamine and 
phaclofen groups displayed an increase thigmotaxis across the two visible days (Figure 
10b; RM-ANOVA; F(3,215) = 6.061, p = 0.001; Tukey post hoc, saline versus ketamine, p 
= 0.001; saline versus phaclofen, p = 0.028). Based on the females’ performance during 
the hidden platform and reversal training days, they received only one day of visible 
training. No significant differences were observed for the latency (Figure 9a; F(3,136) = 
0.086, p = 0.968) and swim speed (Figure 10a; F(3,136) = 2.424, p = 0.069) between 
treatment groups; however, the ketamine treated female group displayed an increased 
thigmotaxis compared to saline (Figure 10b; F(3,136) = 3.165, p = 0.027; Tukey post hoc 
saline versus ketamine, p = 0.025).  
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Figure 9. Morris Water Maze Latency and Probe Trial. (a) Mean latency (±SEM) across 
hidden platform days, reversal, and visible. Male ketamine group took significantly 
longer to find hidden platform across days. No differences were observed in the females. 
* = Significant difference between saline versus ketamine, p < 0.05. (b) Mean percent 
time in quadrant (±SEM) with target versus quadrants for each treatment group. Male 
saline, ketamine, and phaclofen groups and female baclofen and phaclofen group spent 
significantly more time in the target quadrant versus quadrant 1, 2, and 3. * = 
Significantly different from target quadrant, p < 0.05.  
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Figure 10. Swim Speed and Thigmotaxis. (a) Mean swim speed (±SEM) across hidden, 
reversal, and visible days for males and females. No significant differences were 
observed. (b) Mean proportion thigmotaxis (±SEM) across hidden, reversal, and visible 
days for males and females. Ketamine males displayed a significant increase in 
thigmotaxis for hidden, reversal, and visible days while the phaclofen males displayed a 
significant increase on visible days. No differences were observed in the females. * = 
Significantly different from saline, p > 0.05. 
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Tail Flick 
 Tail flick (Figure 11) was performed to examine nociception differences between 
treatment groups following the completion of the Morris water maze. No significant 
differences were observed between treatment groups for males (One-way ANOVA; F(3,51) 
= 0.903, p = 0.446) or females (F(3,31) = 0.691, p = 0.565) indicating no nociceptive 
changes may be related to any differences in the above data.  
 
Figure 11. Tail Flick Latency. Mean latency (±SEM) to remove tail from hot water. No 
differences were observed between treatment groups for males or females.  
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Tissue Analysis 
SDS-PAGE Western Blotting 
 Protein levels of multiple specific receptor subtypes relating to GABA and 
NMDA signaling in the cortex were analyzed via SDS-PAGE/Western blotting. No 
significant differences were observed between treatment groups in the protein levels of 
either of the identified subtypes of the GABAB1 receptor subunit (1a or 1b; Figure 12a) 
for males (1a: F(3,46) = 1.090, p = 0.363; 1b: F(2,46) = 0.591, p = 0.624) or females (1a: 
F(3,41)  = 0.863, p = 0.468; 1b: F(3,41) = 2.639, p = 0.062). Separate analyses were 
performed to examine differences in only the animals treated with the GABAB ligands 
compared to saline. Baclofen and phaclofen treated males did not exhibit any differences 
in protein levels of either of the GABAB1 (1a and 1b) receptor subunit (1a: F(2,33) = 0.666, 
p = 0.521; 1b: F(2,32) = 0.506, p = 0.607). A significant increase was observed in the 
protein levels of the 1b receptor subunit in the phaclofen treated females (F(2,33) = 6.323, 
p = 0.005; Tukey post hoc for saline versus phaclofen, p = 0.004) while no differences 
were detected for the 1b receptor subunit in the post hoc analyses for baclofen treated 
females (Tukey post hoc for saline versus baclofen, p = 0.192). Additionally, no 
differences were detected in the 1a receptor subunit for the baclofen or phaclofen treated 
females (F(2,32) = 0.564, p = 0.574).    
 Evaluation of GABAB2 receptor protein levels in the cortex (Figure 12b) did not 
reveal any significant differences in the males (F(3,59) = 0.930, p = 0.432). However, the 
female phaclofen group displayed a significant increase in expression level GABAB2 
(F(3,41) = 4.919, p = 0.005; Tukey post hoc for saline versus phaclofen, p = 0.003). No 
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differences were found for GABAAα5 protein levels (Figure 12c) between the treatment 
groups in males (F(3,44) = 0.523, p = 0.669) or females (F(3,38)  = 0.471, p = 0.704).  
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Figure 12. GABA Receptor Protein Levels. (a) Proportion (±SEM) and representative 
blots of GABAB1a and GABAB1b protein levels normalized to β-Actin from the cortex. No 
differences were observed between the male treatment groups. Phaclofen treated females 
displayed increased GABAB1b protein levels compared to controls.# = Significantly 
different from saline (baclofen and phaclofen in analysis only), p < 0.05. (b) Proportion 
(±SEM) and representative blots of GABAB2 protein levels normalized to β-Actin from 
the cortex. No differences observed between male treatment groups. Phaclofen treated 
females displayed a significant increase in GABAB2 protein levels. * = Significantly 
different from saline, p < 0.05. (c) Proportion (±SEM) and representative blots of 
GABAα5 protein levels normalized to β-Actin from the cortex. No differences were 
observed between males and females. 
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Protein levels for GAD67 (Figure 13a) were not significantly different between 
treatment groups for males (F(3,50) = 0.568, p = 0.639) or females (F(3,36) = 0.611, p = 
0.612). However, the literature suggests a difference in GAD67 protein levels between 
males versus females related to developmental maturation, therefore additional analysis 
were conducted to directly compare GAD67 protein expression in males and females in 
the same treatment groups (Figure 13b). A significant increase in the GAD67 protein 
expression was observed for the phaclofen treated females compared to the phaclofen 
treated males (F(1,20) = 6.505, p = 0.019) and for the ketamine treated females compared 
to the ketamine treated males (F(1,22) = 9.601, p = 0.005). No differences were seen 
between the male and female saline groups (F(1,18) = 0.047, p = 0.831) or between the 
male and female baclofen groups F(1,22) = 1.577, p = 0.222). 
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Figure 13. GAD67 Protein Levels. (a) Proportion (±SEM) and representative blots of 
GAD67 protein levels normalized to β-Actin from the cortex. No significant differences 
were observed between treatment groups for males or females. (b) Proportion (±SEM) of 
GAD67 protein levels normalized to the males. A significant increase was observed for 
the ketamine treated females compared to ketamine treated males as well as a significant 
increase for GAD67 in the phaclofen treated females compared to phaclofen treated 
males. * = Significantly different from males, p < 0.05. 
 
  The evaluation of the NR2B subunit of the NMDA receptor protein levels (Figure 
14a) revealed no significant differences between treatment groups for males (F(3,51) = 
0.387, p = 0.763) or females (F(3,36)  = 1.151, p = 0.342).  Phaclofen treated females did 
displayed a significantly higher level of the kalirin 5 protein isoform compared to the 
other female treatment groups (Figure 14b; F(3,36) = 4.354, p = 0.010; Tukey post hoc for 
saline versus phaclofen, p = 0.008). No significant differences were found in the other 
kalirin isoforms for the females (Figure 14b; kalirin 7: F(3,36) = 1.208, p = 0.321; kalirin 9: 
F(3,36) = 0.838, p = 0.482; kalirin 12: F(3,36) = 0.542, p = 0.656) and no differences were 
found in protein levels for any of the kalirin isoforms for the males (kalirin 5: F(3,50) = 
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0.880, p = 0.458; kalirin 7: F(3,50) = 0.465, p = 0.708; kalirin 9: F(3,50) = 0.497, p = 0.686; 
kalirin 12: F(3,50) = 1.255, p = 0.300).  
 
 
Figure 14. NR2B and Kalirin Protein Levels. (a) Proportion (±SEM) and representative 
blots of NR2B protein levels normalized to β-Actin from the cortex. No significant 
differences were observed. (b) Proportion (±SEM) and representative blots of kalirin 
protein levels normalized to β-Actin from the cortex. A significant increase was observed 
for kalirin 5 isoform in phaclofen treated females. * = Significantly different from saline, 
p < 0.05.  
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CHAPTER 5 
DISCUSSION 
Administration of ligands that alter the function of GABAB or NMDA receptor 
function during a critical period in early brain development produced a sizable change in 
behavior in adulthood. The early life alterations in GABAB and NMDA receptor 
signaling also produced a change in several proteins in the brain. Specifically, 
administering ketamine on PND 7, 9, and 12 (Hypothesis 1) disrupted responses in PPI 
and performance in the Morris water maze. Additional changes were observed in protein 
expression of GAD67 in males versus females. The administration of GABAB ligands 
(baclofen or phaclofen) in development (Hypothesis 2) altered acoustic startle responses, 
PPI, performance in the Morris water maze, and the expression of multiple proteins 
related to GABAeric signaling as well as a protein implicated in synapse formation. 
These data represent the first reports of a lifelong change in both behavioral and 
biochemical processes associated with early life GABAB receptor function. The deficits 
observed differed based on gender and the specific behavioral task or protein.  
The data in these studies demonstrate behavioral alterations in acoustic startle 
response and PPI in adulthood from the transient enhancement or blockade of the 
GABAB receptor system during development. These findings also lend evidence to the 
importance of these receptors during early brain development. Inhibitory tone mediated 
through GABAB and NMDA receptors in adulthood is necessary for the prepulse to 
reduce the acoustic startle response in PPI. The acoustic startle response is a simple, 
sensorimotor reflex in the presence of fear (Koch & Schnitzler, 1997). In this experiment, 
the male and female treatment groups displayed different behavior in their acoustic startle 
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responses. The male baclofen group displayed an enhanced startle response across 
multiple startle stimuli whereas the female animals administered baclofen displayed a 
decrease in the startle response. The male ketamine group did not display an increase in 
startle response across startle intensities (RM-ANOVA not significant versus saline) and, 
therefore, we cannot state that they exhibited an increase in startle response overall 
despite an increase in startle for the 100 dB startle stimulus. While no differences were 
observed in the male phaclofen group, the female phaclofen group displayed a significant 
reduction in startle response across intensities and, in particular, at the 120 dB level. 
Decreases in acoustic startle response are typically observed after habituation or 
sensitization after repetitive presentations (Pilz & Schnitzler, 1996). In our experimental 
methods, the stimuli are only presented five times randomized throughout the session 
thus insufficient for habituation or sensitization. Based on this, the increase in acoustic 
startle response in the baclofen male group as well as the reduction seen in both the 
baclofen and phaclofen females likely represent a gender dependent disruption to GABA 
signaling involved in the sensorimotor circuitry.   
Assessing the influence of multiple temporal gaps (interstimulus intervals; ISI) 
between the prepulse and the startling stimulus allows for the ability to parse discrete 
regions and transmitter systems involved in the multisensory PPI circuitry. The 
nonstartling prepulse inhibits the reflexive response to a startling stimulus if it precedes 
the startling stimulus between 10-1000 ms (Hoffman & Ison, 1980). By manipulating the 
interval between the prepulse and startle stimulus (ISI), differing neurotransmitter 
systems and brain regions are involved (Hoffman & Ison, 1980; Swerdlow et al., 2001; 
Yeomans et al., 2010). NMDA receptors located in the prefrontal cortex and the 
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hippocampus mediate the inhibition of the prepulse between ISIs of 100-500 ms 
(Swerdlow et al., 2001). Both ionotropic and metabotropic GABA receptors also 
influence the inhibition of the startle response. PPI occurring at shorter ISIs (starting at 
20 ms) are principally governed by GABAA receptors due to the fast acting nature of 
these ionotropic channels (Yeomans et al., 2010). Metabotropic GABAB receptors exhibit 
a longer latency to activate but induce a longer lasting inhibitory effect that can impact 
PPI over a wide range of ISIs beginning at approximately 40 ms ranging to as much as 
500 ms (Yeomans et al., 2010). The combination of GABAA and GABAB receptors allow 
for PPI over the entire range of intervals. The reduction in PPI in the 100 ms ISI trials in 
females administered baclofen, phaclofen, and ketamine with no difference in the male 
animals suggest that the females may be more sensitive to the subtle changes in these 
receptor systems during early brain development. Interestingly, the reduction in PPI 
across multiple prepulse intensities (see Figure 3) is typically seen in patients with 
schizophrenia and animal models of schizophrenia (Bolton et al., 2012; Cilia et al, 1997; 
Mansbach and Geyer 1991; Sabbagh et al., 2012; Swerdlow et al., 1998). One can argue 
that the deficits displayed by the female baclofen and phaclofen in the PPI with 100 ms 
ISI may be due to the reduction of the acoustic startle response. To a certain extent, the 
startle response might have contributed to the deficits seen in the PPI with 100 ms ISI but 
there were no differences in the female baclofen group in the PPI with 40 ms ISI making 
it unlikely that the PPI deficits are an artifact of the reduced startle response.  
The lack of reduction and borderline enhancement of the startle response in PPI is 
extremely rare. More compelling is that at the 40 ms ISI for both the phaclofen treated 
males and females exhibited this deficit, and this is the only difference shared by the 
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males and females in this study. This indicates that, following GABAB receptor 
antagonism in early life, not only did the animals fail to display the normal reduction in 
startle response in the presence of a prepulse, but in some animals, there was an increase 
in the startle response on trials that contained the prepulse. Few reports indicate a change 
similar to those observed with limited data indicating only select stimulants can produce 
this effect (Ashare et al., 2010; Gould et al., 2005). Knockout mice with reduced 
expression of GABAB1 receptors also display an enhanced response with the presence of 
the prepulse (Prosser et al., 2001). However, these mice also experience seizures and 
resemble a model of epilepsy. Further, homozygous knockout of GABAB1 leads to 
premature death. It is plausible that the reduction of GABAB receptors in the knockout 
study may lead to a compensatory gain in systems that affect the PPI circuitry. Although 
our experiment only transiently blocked GABAB receptors at brief intervals in early brain 
development, it is clear that the alteration in GABAB receptor function did alter circuits 
involved in PPI in a similar way as in the knockout study. These data further imply the 
importance of normal functioning of the GABAB receptors during brain development.  
The spatial learning and memory results from the Morris water maze revealed 
some interesting findings. The importance of NMDA receptors during adulthood in 
learning the hidden platform location using spatial cues have been observed in numerous 
studies (Amaral & Witter, 1991; Moser, Moser, & Andersen, 1993; Sabbagh et al., 2012). 
Multiple studies have demonstrated that the administration of NMDA receptor 
antagonists induce deficits in spatial learning and memory (Didriksen, Skarsfeldt, & Arnt, 
2007; Moosavi et al., 2012; Sabbagh et al., 2012). In this experiment, the male ketamine 
group displayed deficits locating the hidden platform across training days indicating 
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impairment in spatial learning; however, the selective search during the probe trial 
suggests they did learn the location using a spatial strategy. There are multiple non-
spatial as well as spatial strategies a subject can use to navigate this maze. The most 
efficient spatial strategy is to immediately orient to the spatial cues in the room once 
placed in the water and swim directly to the hidden platform location, an approach 
commonly seen in controls. A less efficient strategy is a mixture of procedural and spatial 
where the subject explores the maze before locating a specific position then orients itself 
to find the hidden platform location (Vorhees & Williams, 2006). Based on the male 
ketamine group latencies, the selective search during the probe trial, and the high 
thigmotaxis, a possibility exists that these animals did not immediately attend to the 
spatial cues once placed in the maze but instead swam around the perimeter before 
orienting to the general area where the platform was located. This indicates that postnatal 
administration of ketamine to male animals produced a subtle deficit compared to the 
controls in acquiring the location of the hidden platform location but based on the 
selective search during the probe, the animals were able to solve the task. Our data are 
consistent with previous studies administering an alternative NMDA receptor antagonist 
(PCP) during the same developmental time period (PND 7, 9, and 11) in which PCP 
administration demonstrated robust deficits acquiring the hidden platform location across 
days and significantly increased thigmotaxis for male animals but no differences were 
observed for the females (Andersen & Pouzet, 2004). PCP binds the NMDA receptor for 
a longer period of time compared to ketamine (Zukin & Zukin, 1979) which may account 
for more robust deficits observed in developmental PCP administration. Therefore, the 
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data from our experiment demonstrate that impairments in spatial learning and memory 
can result from a subtle disruption in NMDA receptor function during development.    
Few studies have specifically investigated and used ligands that target GABAB 
receptors in spatial learning and memory tasks. Although there are no other studies to 
compare the effects of GABAB receptor alteration in development to adulthood 
performance in the Morris water maze, we did not find any differences in the acquisition 
of the hidden platform training for the baclofen or phacofen treated male animals. 
However, the male baclofen group failed to display a selective search during the probe 
trial. Equivalent performance throughout training and a lack of a selective search during 
the probe trial does indicate an impairment in learning the task (Beiko, Candusso, & 
Cain, 1997; Kinney, Starosta, & Crawley, 2003; Wolfer et al., 1998). One possibility is 
that the baclofen treated males were using a non-spatial strategy such as swimming a 
specific distance from the wall of the maze and eventually bumping into the hidden 
platform (Beiko, Candusso, & Cain, 1997; Kinney, Starosta, Crawley, 2003). Without 
adopting a spatial strategy using the cues to solve the task would explain the nonselective 
search. For the female data, the hidden platform training data suffered considerable 
variability which may have influenced the lack of a difference between treatment groups. 
Both the female saline and ketamine group did not display a selective search during the 
probe trial but it is difficult to interpret the data for the ketamine group when the controls 
failed to demonstrate learning the spatial task. Numerous studies have indicated greater 
variability in female animals performance in the water maze (Andersen and Pouzet, 2004; 
Beiko et al., 2004; Berger et al., 2006; Frick et al., 2000; Wang et al., 2001). Estrogen 
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levels have been demonstrated to influence learning strategy in tasks like the Morris 
water maze which may explain the females’ behavior (Chesler & Juraska, 2000). 
Emotional learning and memory was examined using trace cued and contextual 
fear conditioning. All treatment groups froze equivalently after the CS-US presentations 
on training day, indicating equivalent effects of training and no differences were 
observed during the initial cued fear or contextual fear sessions. All of the male and 
female groups displayed similar extinction to the fear associations as demonstrated by the 
reduction of fear behavior across days. Our laboratory has previously demonstrated 
alterations in ketamine or GABAB receptor function in adulthood alters the cued fear 
association (Bolton et al., 2012; Heaney et al., 2012). Additionally, following the 
administration of ketamine in adult animals an increase in protein levels specific to the 
postsynaptic subunit (1b) of the GABAB receptor was observed in the amygdala (Bolton 
et al., 2012). This suggests an interaction between changes in NMDA receptor function 
and GABAB receptors in fear conditioning (Bolton et al., 2012). Diminished NMDA 
receptor function results in decreased excitation of GABAergic interneurons thus 
diminished GABA release and an alteration in GABA receptors (Bolton et al., 2012; 
Zhang, Behrens, Lisman, 2008). A reduction in NMDA receptor activity is hypothesized 
to be involved in the pathophysiology of schizophrenia so it is logical to determine if a 
change in GABAB receptors produces similar behavioral alterations as a change in 
NMDA receptors as it relates to this disorder. Separate experiments performed in our 
laboratory investigating GABAB receptor function associated with CCF in adult animals 
revealed impaired extinction of the learned association in baclofen administered adult 
animals (Heaney et al., 2012). Therefore, it has been demonstrated that ketamine and 
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baclofen produce deficits in the trace cue fear association which relies on both the 
amygdala and hippocampus (Bolton et al., 2012; Heaney et al., 2012). Since NMDA 
antagonists induce a change in GABAB receptor levels and both NMDA antagonists and 
GABAB agonists produce deficits in fear learning, it is important to investigate the 
adulthood behavioral effects of postnatal alteration of these neurotransmitter systems as it 
relates to CCF. An interesting observation in this current experiment is that the phaclofen 
treated female group displayed a decrease in freezing to the CS following the reminder 
session compared to the controls (Figure 8a). Since there were no differences in freezing 
before the reminder trial, this may indicate that the phaclofen females did not exhibit 
equivalent reinstatement of the fear association compared to controls. Reinstatement is 
the recovery of the fear response following a post-extinction presentation of the CS-US 
(Kim & Richardson, 2007). In neurobiological models of extinction as well as studies 
that demonstrate impaired extinction in rats with medial prefrontal cortex (mPFC) 
lesions, it is theorized that the mPFC inhibits the amygdala by activating GABA 
interneurons during the expression of extinction (Hobin, Goosens, & Maren, 2003; 
Morgan, Schulkin, & LeDoux, 2003; Quirk et al., 2000; Santini et al., 2004; Sotres-
Bayon, Cain, & LeDoux 2006). Adding to this, current neurobiological models of 
extinction maintain that the hippocampus modulates the expression of learned fear or 
extinction by inhibiting or exciting the mPFC (Hobin, Goosens, & Maren, 2003; Kim & 
Richardson, 2007). The CS-US reminder triggers the hippocampal inhibition of the 
mPFC, preventing the mPFC from inhibiting the amygdala following extinction. From 
this model, we can infer from the reinstatement deficit observed in the phaclofen treated 
females that disrupted GABA signaling within the hippocampus-mPFC-amygdala 
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network may have contributed to a reduction in reinstatement of the conditioned fear. 
While this change is subtle, it does indicate an alteration in Pavlovian learning as a result 
of phaclofen administration in early life.      
In order to examine if alterations in specific proteins may be related to the 
behavioral changes observed in the present experiments, we performed SDS-PAGE 
directed at multiple GABA, NMDA, and associated targets in all groups. We also 
investigated if any changes were observed in the kalirin protein that is associated with 
synapse formation and remodeling and has also been found to be altered in schizophrenia. 
Cortex samples were evaluated based on previous literature indicating alterations in 
GABAergic function being related to deficits in behavioral tasks and patient post-mortem 
tissue in this region (Fatemi, Folsom, Thuras, 2011; Guidotti et al., 2000; Ishikawa et al., 
2005; Swerdlow et al., 2001; Woolley et al., 2013). The GABAB receptor is composed 
two distinct subunits, GABAB1 and GABAB2. Distinct GABAB1 isoforms have been 
determined to be specific to either the presynaptic (1a) or postsynaptic (1b) expression 
(Steiger et al., 2004). The phaclofen treated females displayed a significant increase in 
the postsynaptic (1b) isoform of the GABAB receptor. Combined with the increased 
expression in the GABAB2 receptor subunit for the phaclofen treated females, these data 
indicate there may be an overall increased expression of postsynaptic GABAB receptors. 
This suggests that an increase in the expression of postsynaptic GABAB receptors 
resulted from the brief antagonism of GABAB receptors during development. An increase 
in postsynaptic receptors in the phaclofen treated females may be related to the deficits 
observed in the acoustic startle response and PPI at multiple intervals. The 
neurotransmitter acetylcholine is necessary to produce the startle response in both the 
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acoustic startle and PPI and is regulated by inhibitory circuits (Swerdlow et al., 200l; 
Yeomans et al,. 2010). The decrease in PPI observed indicates a lack of reduction in the 
startle response in the presence of the prepulse. These data, coupled with the increase in 
postsynaptic GABAB receptors, may reflect diminished GABA tone thus a lack of 
inhibition on cholinergic neurons. However, the extent to which this increase in protein 
resulted in functional GABAB receptors remains to be determined as well as the time 
point at which this increase occurred (in development, adolescence, or adulthood).  
We investigated other GABA related proteins that have been implicated in PPI 
and schizophrenia as well as those that may be related to a change in GABA signaling. 
GABAAα was examined for protein differences between treatment groups as a reduction 
has been demonstrated following PPI deficits, similar to the ones observed in this study 
(Hauser et al., 2005). However, no differences were seen in the GABAAα5 receptor, which 
indicates the early life treatment did not induce a change in all GABAergic signaling 
targets.   
Evidence suggests that increases in GAD67 levels positively correlate with 
GABA release. Although no differences existed between treatment groups within each 
gender, we examined if the treatment had differential effects comparing genders. 
Changes in GAD67 mRNA are influenced by steroid hormones such as progesterone and 
estrogen (McCarthy et al., 1995; Perrot-Sinal, Davis, McCarthy, 2001; Searles et al., 
2000). However, there are conflicting reports on GAD67 expression as either being 
increased or decreased in the presence of estrogen (McCarthy et al., 1995; Souza et al., 
2009). Based on the sexually dimorphic expression of GAD67, we examined whether the 
effect of treatment may influence expression of this protein between genders. The data 
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indicated a significant increase in the females when normalized to males of the same 
treatment, indicating a difference between gender in the ketamine and phaclofen treated 
animals. Studies demonstrate that GABA exerts a negative feedback effect on the 
expression of GAD67 in vivo and in vitro and GAD67 is particularly sensitive to changes 
in GABA (Rimvall & Martin, 1994). An increased expression in GAD67 protein may 
indicate a reduction in GABA levels in the cortex. The increased expression of GAD67 in 
the ketamine treated females compared to ketamine treated males may explain the sex 
differences observed in PPI with 100 ms ISI. Since GABA is necessary for the inhibition 
of this task, altered GABA levels as indicated by increased GAD67 expression may 
account for the deficit. In addition, expression of GAD67 in the phaclofen treated females 
(compared to the phaclofen treated males) was increased. Based on data that indicate an 
inverse relation between GAD67 protein expression and GABA levels as well as our 
findings that GABAB1b and GABAB2 protein levels are increased in phaclofen treated 
females, these results may indicate decreased GABA levels in the prefrontal cortex of 
these animals.  Reduced GABA levels would explain the PPI with 100 ms ISI deficits and 
possibly the lack of reinstatement in CCF for the phaclofen treated females. The 
expression of GAD67 was not changed between genders for the saline and baclofen 
group which means the changes are specific to the phaclofen and ketamine treated 
groups. The data suggest that the blocking either the GABAB or the NMDA receptor 
during this developmental time point had a greater impact on the female developing 
nervous system compared to the male.  
As GABAB has been implicated in numerous processes underlying neuronal 
migration and synapse formation (Ben-Ari et al., 2007; Huang, Di Cristo, & Ango, 2007; 
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Gaiarsa et al., 2011; Owens & Kriegstein, 2002; Represa & Ben-Ari, 2005;), we also 
investigated if changes in proteins associated with synaptogenesis and remodeling were 
observed in the treatment groups. One protein in particular, kalirin, has been found to 
serve a role in synapse formations and restructuring (Ma et al., 2008). Differential 
expression of kalirin isoforms has also been observed in post-mortem analysis of patients 
with schizophrenia. Some studies report an increase in expression (Deo et al., 2012) 
while others report a decreased expression (Hill, Hashimoto, Lewis, 2006; Penzes & 
Remmers, 2012) in the prefrontal cortex. In our experiment, the phaclofen treated 
females displayed an increase in protein expression levels for kalirin 5. An excess of 
kalirin indicates that the mechanisms involved in synapse formation are dysregulated, 
which may be associated with excessive attempts to build synapses (Penzes & Remmers, 
2012). This may indicate a role for GABAB receptors in regulating synapse formation 
during early brain development. This can also be related to the increased expression in 
the other proteins examined (postsynaptic GABAB receptors and GAD67) in that altered 
function of GABAB receptors results in dysregulated synapse formation leading to 
behavioral deficits in the female animals. However, this theory requires further 
investigation.   
The most apparent differences in the above study were reflected in the female 
treatment groups. These findings were unexpected as we did not anticipate the 
differences between the sexes. Few studies include females in both behavioral and 
biochemical experimental conditions, especially studies that focus on animal models of 
schizophrenia. Most animal studies utilize exclusively male rodents as opposed to 
females unless the researchers are interested in the influence of hormones (estrogens). 
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Interestingly, estrogen has been demonstrated to be neuroprotective against cellular 
dysfunction and damage, which has been shown in vitro and in vivo (see Singh, Dykens, 
Simpkins, 2006). Separately, studies by Woolley (1997, 1998) reveal that chronic 
administration of estradiol increase NMDA receptor expression and sensitivity to 
glutamate. During the proestrus phase of a rodent estrous cycle, when estrogen levels are 
at their peak, the number of synapses in the hippocampus increased by 30% compared to 
the estrous phase when estrogen levels are the lowest (Warren and Juraska, 1997). The 
drastic change in hippocampal morphology across the rodent estrous cycle is further 
complicated by the length of the cycle. The estrous cycle of a rodent is very short (four 
days) and influences their behavior in multiple tasks including PPI (Koch, 1998) and 
learning and memory tasks (for review, see Dohanich, 2002). Investigations using female 
rodents include initial tests for phase in the estrous cycle using a variety of methods. In 
this experiment, estrous phase was not examined; however, all females were housed in 
the same colony room. Based on previously established studies that mammalian females 
synchronize their ovarian cycles while living in close proximity (see McClintock, 1984), 
we elected to not examine the phase of estrous. Instead, we pseudo randomized the pair-
housed cage assignments between treatment groups in the colony room.  If there were 
differences in the phase of cycle between animals, we tried to minimize the effect it may 
have had in one treatment group versus another. Future studies performed in our 
laboratory with females will incorporate estrous phase testing to ensure all animals are in 
the same phase. 
In this current experiment, the hormonal regulation of developmental processes 
may have played a larger role than we had initially hypothesized. Estrogen and 
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progesterone receptors are abundant in brain regions involved in reproduction but they 
are also found in smaller concentrations in regions such as the basal forebrain, 
hippocampus, and cortex. Estrogen and progesterone binding to these receptors affect the 
rates at which proteins are synthesized (Dohanich, 2003). For example, estrogen and 
progesterone secreted by the ovaries or exogenously administered can alter enzymes, 
receptors, transporters, and other proteins associated with glutamate and GABA signaling 
(Daniel & Dohanich, 2001). During development, the estradiol concentrations are the 
same in neonatal male and female animals (Amateau et al., 2004; McCarthy & Konkle, 
2005; Nunez and McCarthy, 2008). Sexual differentiation appears during the first to 
second week of life due to a perinatal testosterone surge in male rodents (Ravizza et al., 
2003; Galanopoulou, 2008). As it relates to the NMDA and GABA signaling, the sex 
dependent change that occurs during this early period in the rodent life is the differential 
expression of the neuronal Cl--extruding K+/Cl- co-transporter (KCC2; promotes chloride 
extrusion). As outlined, GABA in development is excitatory when acting upon pyramidal 
GABAA receptors until after the end of first postnatal week of life in a rat (Ben-Ari et al., 
1989). These effects are due to the relatively high expression of the Na2+/K+/Cl- co-
transporter 1 (NKCC1; promotes Cl- entry into the cell) and the low expression of the 
KCC2 which results in a high intracellular Cl- concentration (Ben-Ari, 2002; Damborsy 
& Winzer-Serhan, 2012; Payne, Stevenson, Donaldson, 1996; Rivera et al., 1999). After 
the first postnatal week of life in a rat, NKCC1 is downregulated and KCC2 is 
upregulated, allowing Cl- to be expelled out of the cells which results in a shift of GABA 
binding GABAA receptors to induce an inhibitory post synaptic potential (Ben-Ari, 2002; 
Rivera, 1999). This process is sex dependent as it occurs earlier in females compared to 
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males (Damborsky & Winzer-Serhan, 2012; Galanopoulou, 2008; Nunez & McCarthy, 
2007). Therefore, the differences observed between males and females in the present 
experiments may be due to the administration of ligands during the time this shift occurs 
and the extended duration of GABA-mediated excitation in the multiple male brain 
regions (Nunez and McCarthy, 2007; Galanopoulou, 2008). The administration of 
GABAB and NMDA ligands during this postnatal time period would then produce 
differential effects in males and females. In the current investigation, we observed 
multiple deficits in female animals following changes in GABAB receptor function. 
Given that the switch from excitatory to inhibitory occurred during the same time frame 
as when these drugs were administered in females (as this switch happens earlier 
compared to males), it is possible that alterations in receptor systems from the drug 
administration presented substantial problems in the females. This may also account for 
the lack of deficits in the males as the drug administration occurred prior to this switch in 
depolarizing effects of GABA on GABAA receptors. The increase in inhibition during 
development as seen in the females during the drug administration period may represent a 
critical period that, when disrupted, results in lifelong alterations. By blocking GABAB 
receptors in females, the inhibition by which they rely may have greater effects. This may 
be a potential explanation for the deficits observed in this experiment and the changes in 
protein expression of multiple GABA related markers. Administering GABAB ligands at 
different developmental time points might further elucidate the effects of GABAB 
receptors and this excitatory to inhibitory shift in early brain develop.    
 These experiments were performed to determine if early life changes in NMDA or 
GABAB receptors would produce alterations with relevance to schizophrenia. Despite a 
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lack of a comprehensive demonstration of schizophrenia deficits in these animals, several 
groups did exhibit deficits related to the disorder. For the behavioral tasks, the phaclofen 
and baclofen treated females as well as the ketamine treated males exhibited deficits in 
the PPI with 100 ms ISI and only the ketamine male animals demonstrated subtle spatial 
learning and memory deficits. Although there were increases in the protein expression of 
multiple markers examined for the phaclofen treated females, our data do not agree with 
the protein changes observed in the post-mortem studies except for the increase in kalirin 
5. Typically, the patient population exhibits a reduction in GABAB receptor proteins, 
GABAAα5, GAD67, and NR2B (Fatemi, Folsom, Thuras, 2011; Guidotti et al., 2000; 
Hauser et al., 2005; Ishikawa et al., 2005; Mizukami, 2000, 2002; Zai et al., 2005) 
whereas the differences observed in this study demonstrated only increased expression in 
a subset of these proteins. In addition, sex differences exist in the schizophrenia patient 
population. These include men exhibiting more negative symptoms compared to women 
(see Leung & Chue, 2000). The results from our study comparing males versus females 
do not reflect what is seen in the patient population.  
 Regardless of how these results relate to schizophrenia, the deficits between the 
treatment groups are intriguing. A subtle alteration of these receptor systems in early 
brain development produced a lifelong behavioral change as evidenced by deficits in PPI, 
learning and memory, and changes in several protein levels. This study supports a role for 
precise signaling of the GABAB and NMDA receptors within specific time periods in 
mammalian brain development. These neurotransmitter systems are involved in 
establishing early neuronal networks (Komuro & Rakic, 1993; LoTurco, Blanton, & 
Kriegstein, 1991; Uhlhaas et al., 2010), and slight alterations in GABAB or NMDA 
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receptor mediated signaling may be sufficient to permanently alter connectivity that 
persists into adulthood. Although other neurodevelopmental studies administering 
NMDA receptor antagonist produced similar and differing deficits, most use more potent 
drugs such as PCP and MK-801 and some studies inject the drug for multiple consecutive 
days (Andersen and Pouzet, 2004; Broberg et al., 2010; Harich, Gross, Bespalov, 2007; 
Takahashi et al., 2006; Wang et al., 2001). Our study set out to examine subtle alterations 
in the NMDA receptor in development rather than a robust reduction in its function. To 
our knowledge, this study is the first to assess the effects in adulthood on behavioral and 
specific protein levels of early postnatal administration of a GABAB receptor agonist and 
antagonist. The deficits produced by both ligands establish the importance of the GABAB 
receptor and pave the way for future studies to further elucidate the role of GABAB 
receptors in development and their possible involvement in neurodevelopmental 
disorders. 
 Additional investigations are required to elucidate the mechanisms involved in 
disruption the GABAB and NMDA receptors in early brain development. Examining the 
effects of several concentrations and multiple time points in development would aid in 
the characterization of the role of these receptor systems in development. Further protein 
analysis of additional brain regions and protein markers may also provide insight into the 
mechanisms involved. The data from this study provide only a glimpse of the importance 
of normal function of the GABAB and NMDA receptors in early brain development.   
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